

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Emerging therapies for hemophilia: controversies... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-489/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-489" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Emerging therapies for hemophilia: controversies and unanswered questions" />
    
            <meta name="og:title" content="F1000Research Article: Emerging therapies for hemophilia: controversies and unanswered questions.">
            <meta name="og:description" content="Read the latest article version by Valder R. Arruda, Bhavya S. Doshi, Benjamin J. Samelson-Jones, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="13525">
            <meta name="article-id" content="12491">
            <meta name="dc.title" content="Emerging therapies for hemophilia: controversies and unanswered questions">
            <meta name="dc.description" content="Several new therapies for hemophilia have emerged in recent years. These strategies range from extended half-life factor replacement products&amp;nbsp;and non-factor options&amp;nbsp;with improved pharmacokinetic profiles to gene therapy aiming for phenotypic cure. While these products have the potential to change hemophilia care dramatically, several challenges and questions remain regarding broader applicability, long-term safety, and which option to pursue for each patient. Here, we review these emerging therapies with a focus on controversies and unanswered questions in each category.">
            <meta name="dc.subject" content="hemophilia, EHL, NFT, gene therapy">
            <meta name="dc.creator" content="Arruda, Valder R.">
            <meta name="dc.creator" content="Doshi, Bhavya S.">
            <meta name="dc.creator" content="Samelson-Jones, Benjamin J.">
            <meta name="dc.date" content="2018/04/24">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.12491.1">
            <meta name="dc.source" content="F1000Research 2018 7:489">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="hemophilia">
            <meta name="prism.keyword" content="EHL">
            <meta name="prism.keyword" content="NFT">
            <meta name="prism.keyword" content="gene therapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/04/24">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="489">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.12491.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-489">
            <meta name="citation_title" content="Emerging therapies for hemophilia: controversies and unanswered questions">
            <meta name="citation_abstract" content="Several new therapies for hemophilia have emerged in recent years. These strategies range from extended half-life factor replacement products&amp;nbsp;and non-factor options&amp;nbsp;with improved pharmacokinetic profiles to gene therapy aiming for phenotypic cure. While these products have the potential to change hemophilia care dramatically, several challenges and questions remain regarding broader applicability, long-term safety, and which option to pursue for each patient. Here, we review these emerging therapies with a focus on controversies and unanswered questions in each category.">
            <meta name="citation_description" content="Several new therapies for hemophilia have emerged in recent years. These strategies range from extended half-life factor replacement products&amp;nbsp;and non-factor options&amp;nbsp;with improved pharmacokinetic profiles to gene therapy aiming for phenotypic cure. While these products have the potential to change hemophilia care dramatically, several challenges and questions remain regarding broader applicability, long-term safety, and which option to pursue for each patient. Here, we review these emerging therapies with a focus on controversies and unanswered questions in each category.">
            <meta name="citation_keywords" content="hemophilia, EHL, NFT, gene therapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Valder R. Arruda">
            <meta name="citation_author_institution" content="The Children's Hospital of Philadelphia, Philadelphia, PA, USA">
            <meta name="citation_author_institution" content="Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA">
            <meta name="citation_author_institution" content="Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, USA">
            <meta name="citation_author" content="Bhavya S. Doshi">
            <meta name="citation_author_institution" content="The Children's Hospital of Philadelphia, Philadelphia, PA, USA">
            <meta name="citation_author" content="Benjamin J. Samelson-Jones">
            <meta name="citation_author_institution" content="The Children's Hospital of Philadelphia, Philadelphia, PA, USA">
            <meta name="citation_author_institution" content="Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA">
            <meta name="citation_publication_date" content="2018/04/24">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="489">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.12491.1">
            <meta name="citation_firstpage" content="489">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-489/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-489.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=13525 /> <input type=hidden id=articleId name=articleId value=12491 /> <input type=hidden id=xmlUrl value="/articles/7-489/v1/xml"/> <input type=hidden id=xmlFileName value="-7-489-v1.xml"> <input type=hidden id=article_uuid value=c5614d1c-17a0-4441-94b1-f0ee8a75bae8 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Emerging therapies for hemophilia: controversies and unanswered questions"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.12491.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.12491.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-489"
  },
  "headline": "Emerging therapies for hemophilia: controversies and unanswered questions",
  "datePublished": "2018-04-24T09:56:35",
  "dateModified": "2018-04-24T09:56:35",
  "author": [
    {
      "@type": "Person",
      "name": "Valder R. Arruda"
    },    {
      "@type": "Person",
      "name": "Bhavya S. Doshi"
    },    {
      "@type": "Person",
      "name": "Benjamin J. Samelson-Jones"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Several new therapies for hemophilia have emerged in recent years. These strategies range from extended half-life factor replacement products and non-factor options with improved pharmacokinetic profiles to gene therapy aiming for phenotypic cure. While these products have the potential to change hemophilia care dramatically, several challenges and questions remain regarding broader applicability, long-term safety, and which option to pursue for each patient. Here, we review these emerging therapies with a focus on controversies and unanswered questions in each category."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-489.html",
            "name": "Emerging therapies for hemophilia: controversies and unanswered questions"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Emerging therapies for hemophilia: controversies and unanswered questions </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=13525 data-id=12491 data-downloads="" data-views="" data-scholar="10.12688/f1000research.12491.1" data-recommended="" data-doi="10.12688/f1000research.12491.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-489/v1/pdf?article_uuid=c5614d1c-17a0-4441-94b1-f0ee8a75bae8" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-12491-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-12491-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-12491-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Arruda VR, Doshi BS and Samelson-Jones BJ. Emerging therapies for hemophilia: controversies and unanswered questions [version 1; peer review: 4 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):489 (<a class=new-orange href="https://doi.org/10.12688/f1000research.12491.1" target=_blank>https://doi.org/10.12688/f1000research.12491.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-12491-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=12491 id=track-article-signin-12491 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/12491?target=/articles/7-489.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=13525 /> <input name=articleId type=hidden value=12491 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Emerging therapies for hemophilia: controversies and unanswered questions</h1><span class=other-info> [version 1; peer review: 4 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:arruda@email.chop.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Valder R. Arruda</span></a><a href="https://orcid.org/0000-0002-8100-5481" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8100-5481</div><sup>1-3</sup>,&nbsp;</span><span class="">Bhavya S. Doshi<sup>1</sup>,&nbsp;</span><span class="">Benjamin J. Samelson-Jones<sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:arruda@email.chop.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Valder R. Arruda</span></a><a href="http://orcid.org/0000-0002-8100-5481" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8100-5481</div><sup>1-3</sup>,&nbsp;</span><span class="">Bhavya S. Doshi<sup>1</sup>,&nbsp;</span><span class="">Benjamin J. Samelson-Jones<sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 24 Apr 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.12491.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> The Children's Hospital of Philadelphia, Philadelphia, PA, USA<br/> <sup>2</sup> Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA<br/> <sup>3</sup> Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, USA<br/> <p> <div class=margin-bottom> Valder R. Arruda <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Bhavya S. Doshi <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Benjamin J. Samelson-Jones <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=33607-33166></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=33610-33167></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=33609-33168></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=33608-33169></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Several new therapies for hemophilia have emerged in recent years. These strategies range from extended half-life factor replacement products&nbsp;and non-factor options&nbsp;with improved pharmacokinetic profiles to gene therapy aiming for phenotypic cure. While these products have the potential to change hemophilia care dramatically, several challenges and questions remain regarding broader applicability, long-term safety, and which option to pursue for each patient. Here, we review these emerging therapies with a focus on controversies and unanswered questions in each category. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> hemophilia, EHL, NFT, gene therapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Valder R. Arruda (<a href="mailto:arruda@email.chop.edu">arruda@email.chop.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Valder R. Arruda </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> BSJ is an investigator on AAV gene therapy clinical trials for hemophilia sponsored by Spark Therapeutics. VRA and BSD declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> VRA is supported by 1R01HL137335 from NHLBI/NIH. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Arruda VR <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Arruda VR, Doshi BS and Samelson-Jones BJ. Emerging therapies for hemophilia: controversies and unanswered questions [version 1; peer review: 4 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):489 (<a href="https://doi.org/10.12688/f1000research.12491.1" target=_blank>https://doi.org/10.12688/f1000research.12491.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 24 Apr 2018, <b>7</b>(F1000 Faculty Rev):489 (<a href="https://doi.org/10.12688/f1000research.12491.1" target=_blank>https://doi.org/10.12688/f1000research.12491.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 24 Apr 2018, <b>7</b>(F1000 Faculty Rev):489 (<a href="https://doi.org/10.12688/f1000research.12491.1" target=_blank>https://doi.org/10.12688/f1000research.12491.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d3141e196>Introduction</h2><p class="" id=d3141e199>Hemophilia is an X-linked bleeding disorder resulting from deficiency of factor VIII (FVIII) or factor IX (FIX) due to mutations in the <i>F8</i> or <i>F9</i> genes, respectively. The disorder affects approximately 1 in 10,000 male births worldwide; 80% of cases are of FVIII deficiency or hemophilia A (HA), and 20% are FIX deficiency or hemophilia B (HB).</p><p class="" id=d3141e208>The disease phenotype is characterized by bleeding into the joints (hemarthrosis), skeletal muscle, soft tissues, and enclosed spaces such as the intracranium and retroperitoneum, which can be fatal. Residual factor level correlates directly with bleeding phenotype wherein patients with severe disease (&lt;1%) present with spontaneous bleeds, those with moderate disease (1–5%) bleed with minor trauma and rarely spontaneously, and those with mild disease (6–30%) bleed only secondary to trauma or invasive procedures. Current treatment includes replacement therapy with plasma-derived (pd) or recombinant (r) clotting factor concentrates either “on demand” for acute bleeding or prophylactically to prevent bleeding. However, in the US, only approximately 60% of young adults and adults report adherence to prophylaxis, and the average cost of the recommended dose of prophylactic therapy is estimated at approximately $200,000–300,000/year<sup><a href="#ref-1">1</a></sup>. Owing to the high cost and need for life-long therapy, only 20% of patients worldwide have regular access to treatment.</p><p class="" id=d3141e215>Currently, the most serious complication of hemophilia therapy is the formation of neutralizing alloantibodies (inhibitors) that preclude the hemostatic effect of factor replacement. In HA, 30% of severe patients and 5–10% of non-severe patients develop inhibitors compared to only 3–5% of severe HB patients<sup><a href="#ref-2">2</a></sup>. Inhibitors are associated with increased morbidity and mortality, and only a few variably effective and expensive hemostatic options (termed bypassing agents) are available to these patients, such as activated prothrombin complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa). Inhibitors do not respond well to immunosuppressive therapy alone<sup><a href="#ref-3">3</a></sup>. The most efficacious and cost-effective treatment for inhibitors is immune tolerance induction (ITI), which consists of frequent injections of FVIII or FIX for extended periods of time. The success rate of inhibitor eradication is 60% and 30% for HA and HB patients, respectively<sup><a href="#ref-4">4</a></sup>. Thus, the development of novel strategies that could facilitate prophylaxis for patients with and without inhibitors is needed (<a href="#f1">Figure 1</a>).</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/13525/b1ca17c6-64ee-4223-9fa9-d2f5e8482e19_figure1.gif"><img alt="b1ca17c6-64ee-4223-9fa9-d2f5e8482e19_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/13525/b1ca17c6-64ee-4223-9fa9-d2f5e8482e19_figure1.gif"></a><div class=caption><h3>Figure 1. Mechanism of action of hemophilia therapies.</h3><p id=d3141e243>Factor X (FX) can be activated to FXa either via FIXa–FVIIIa complex or the tissue factor (TF) factor–FVIIa complex. FXa and FVa activate prothrombin (FII) to thrombin (FIIa) in order to generate a fibrin clot. Natural anti-coagulants targeted by non-factor therapeutics are represented in red. Protein-based therapeutics are represented in purple, nucleotide-based therapeutics are represented in blue, and antibody-based therapeutics are represented in green. Fitusiran decreases the production of antithrombin (AT), decreasing its inhibition of FIXa, FXa, and FIIa. Concizumab and anti-protein C serine protease inhibitors (serpins) block tissue factor pathway inhibitor (TFPI) from inhibiting FXa and TF–FVIIa complex or protein C from inhibiting FVIIIa and FVa, respectively. Emicizumab is a FVIIa mimic that brings together FIXa and FX to generate FXa. Factor-based therapies include adeno-associated virus (AAV)-based liver-directed gene therapy, which results in endogenous factor production, and exogenously given factor therapeutics given intravenously. APC, activated protein C; EHL, extended half-life.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3141e253>Extended half-life products</h2><p class="" id=d3141e256>The half-lives of FVIII and FIX in plasma are 10–12 hours and 16–18 hours, respectively<sup><a href="#ref-5">5</a></sup>. For prophylaxis, patients with severe disease need to be injected with standard half-life (SHL) replacement therapy two to three times per week to minimize spontaneous bleeds by maintaining a factor level &gt;1%. Consequently, pharmaceutical development has focused on the optimization of product pharmacokinetics to decrease infusion frequency. Technologies used to create these extended half-life (EHL) products decrease clearance by fusion to the constant fragment (Fc) of IgG or albumin, PEGylation (the covalent attachment of polymeric hydrophilic polyethylene glycol [PEG] molecules), or protein modifications<sup><a href="#ref-6">6</a></sup>. Alternative strategies to extend half-life such as carboxy-terminal peptide technology, hydroxyethyl starch, and hyperglycosylation are still in early preclinical phases. Fusion technologies avoid lysosomal degradation of the protein by utilizing the neonatal Fc receptor to salvage factor proteins and recycle them into the circulation<sup><a href="#ref-7">7</a></sup>. PEGylation increases half-life by reducing proteolytic cleavage and inhibiting receptor-mediated clearance<sup><a href="#ref-8">8</a></sup>.</p><div class=section><a name=d3141e275 class=n-a></a><h3 class=section-title>Are EHL products “better”?</h3><p class="" id=d3141e280>EHL–rFIX products have successfully decreased infusion frequency from twice weekly to every 10–14 days using fusion to Fc–IgG1 or albumin or PEGylation technologies<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>; however, EHL–rFVIII products have only decreased infusions from about three to about two times per week<sup><a href="#ref-11">11</a>–<a href="#ref-13">13</a></sup>. Efforts are underway to understand why EHL–rFVIII products have not been more successful. Clearance of FVIII from the circulation occurs mostly in complex with von Willebrand factor (VWF); the half-life of VWF ranges from 4–26 hours, with an average of approximately 15 hours<sup><a href="#ref-14">14</a></sup>. The prevailing theory is that the half-life of VWF imposes an upper limit on FVIII half-life prolongation. Two recent studies evaluating the biochemical interaction between VWF and FVIII demonstrated that it was dependent upon the VWF D’D3 and FVIII C1 domains<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup>. Preclinical studies are now assessing VWF D’D3 and/or FVIII protein modifications to enhance VWF binding or half-life<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>. All licensed EHL products recommend tailoring the dose to the individual patient’s pharmacokinetic response. Hence, for each individual patient, a particular product may not offer significant half-life extension and therefore may be less effective from a cost and convenience standpoint. However, EHL products might afford clinicians the ability to customize a patient’s dose and frequency for a higher goal factor trough that minimizes bleeding and maximizes compliance. Indeed, post-hoc analysis of rFVIII–Fc trials demonstrates improved bleeding rate with similar or increased physical activity<sup><a href="#ref-19">19</a></sup> and improved joint arthropathy scores in patients treated with rFVIII–Fc either prophylactically or on demand<sup><a href="#ref-20">20</a></sup>. These benefits likely reflect higher troughs and improved compliance secondary to decreased infusion frequency with EHL products.</p></div><div class=section><a name=d3141e325 class=n-a></a><h3 class=section-title>Are EHL products safer?</h3><p class="" id=d3141e330>Whether the EHL products alter the immunogenicity profile of rFVIII products and might be safer than pdFVIII–VWF products is an unanswered question. There is only one reported case of inhibitor development to date for EHL products<sup><a href="#ref-21">21</a></sup>. Early data support the hypothesis that Fc fusion may potentially decrease immunogenicity in previously treated patients, but analogous data for previously untreated patients are not yet available. To date, seventeen patients with inhibitors have been successfully tolerized with rFVIII–Fc, including some who had previously failed ITI with SHL rFVIII<sup><a href="#ref-22">22</a>–<a href="#ref-24">24</a></sup>. The success of this strategy is likely due to a longer time with consistent antigen exposure with rFVIII–Fc<sup><a href="#ref-25">25</a></sup>. Furthermore, in murine studies, treatment with rFVIII–Fc expanded tolerance-inducing regulatory T cells<sup><a href="#ref-26">26</a></sup>. A clinical trial for immune tolerance therapy with rFVIII–Fc as first-line therapy is ongoing (NCT03093480). The available data suggest that the immune profile of EHL products is similar to, if not better than, SHL recombinant products. There are no data available comparing recombinant EHL with plasma-derived factors.</p><p class="" id=d3141e352>However, half-life-extending strategies utilizing protein sequence changes in the bypassing agent rFVIIa have proven problematic. Two different EHL rFVIIa products with changes in protein sequence to enhance stability progressed through early trials, but patients in later-phase trials developed inhibitors to the investigational drug that cross-reacted to endogenous FVIIa<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. These failures underscore the importance of further characterizing the immune response to novel products, especially with amino acid changes, in order to better predict immunogenicity in patients<sup><a href="#ref-29">29</a></sup>. For PEGylated products, long-term follow-up is needed to understand the implication of anti-PEG antibodies and whether significant PEG accumulation occurs, as was demonstrated in animal models<sup><a href="#ref-30">30</a></sup>. Currently available data suggest that albumin-fused rFIX provides a similar dosing frequency to PEGylated rFIX without the theoretical concern of PEG accumulation<sup><a href="#ref-9">9</a></sup>.</p></div><div class=section><a name=d3141e375 class=n-a></a><h3 class=section-title>Does switching product affect safety of treatment?</h3><p class="" id=d3141e380>There are no randomized trial data to understand whether switching a patient from one product to another will change the risk of inhibitor formation. Inhibitors typically occur within the first 50 exposure days to factor in severe patients<sup><a href="#ref-31">31</a></sup>. Prior studies done after national health services required a change in FVIII product have found varied results<sup><a href="#ref-32">32</a>–<a href="#ref-36">36</a></sup>. Consequently, providers who switch products do so carefully with inhibitor titers pre- and post-switch and generally avoid switching in patients with a history of inhibitor who have been tolerized with a specific product.</p><p class="" id=d3141e394>The devastating HIV and viral hepatitis epidemics amongst people with hemophilia from viral contamination of plasma-derived products in the 1980’s spurred the development and transition to recombinant products<sup><a href="#ref-37">37</a>,<a href="#ref-38">38</a></sup>. However, long-standing debate has ensued in the field regarding the relative immunogenicity of pdFVIII and SHL rFVIII products because of conflicting results of retrospective studies<sup><a href="#ref-39">39</a>–<a href="#ref-42">42</a></sup>. Recently, the only prospective, randomized trial (SIPPET) comparing the immunogenicity of VWF-containing pdFVIII products to SHL rFVIII products in HA demonstrated increased immunogenicity with SHL rFVIII (hazard ratio 1.86)<sup><a href="#ref-43">43</a></sup>. How best to apply these results in clinical decision making is complicated by the emergence of EHL–rFVIII products since SIPPET. EHL products, especially EHL–rFIX, may increase compliance by decreasing infusion frequencies, but it is unknown if EHL–rFVIII products are more or less immunogenic than SHL rFVIII or pdFVIII products. Although certain factors can guide clinicians to risk of inhibitor formation (e.g. disease severity, underlying mutation, and family history), inhibitor risk stratification is an imprecise science<sup><a href="#ref-44">44</a></sup>. Furthermore, in SIPPET subanalysis, use of pdFVIII versus SHL rFVIII surprisingly proved beneficial only for “low”- rather than “high”-risk patients<sup><a href="#ref-45">45</a></sup>. SIPPET results also pose a dilemma for clinicians who are hesitant to return to pdFVIII because of the history of prior blood-borne infectious epidemics or the potential for new ones. Though current virucidal techniques to date have successfully mitigated the risk of emerging viruses (e.g. West Nile<sup><a href="#ref-46">46</a></sup> and Zika<sup><a href="#ref-47">47</a></sup> virus), the risk posed by prions<sup><a href="#ref-48">48</a></sup> and other unidentified infectious agents remains unknown. Preliminary data also suggest that EHL products may fare better for ITI<b>,</b> both for those who fail with rFVIII and as first-line therapy<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>.</p><p class="" id=d3141e446>In conclusion, clinicians face a litany of challenging choices for factor replacement. They are tasked with prioritizing convenience, cost, compliance, and safety without definitive ability to predict immune or product pharmacokinetic responses. Though it is tempting to “move backwards” to pdFVIII based upon SIPPET and improved viral inactivation techniques, the potential of a novel blood-borne pathogen epidemic should engender caution. As inhibitors occur in only 20–30% of severe patients, the economic impact of widespread use of pdFVIII (as implied by recent risk-stratified SIPPET subanalysis<sup><a href="#ref-45">45</a></sup>) should be considered as national groups develop guidelines. Further insight into the basic mechanisms underlying FVIII immunogenicity and clearance, the role of VWF in both, and clear risk stratification schema for inhibitor formation will tremendously advance the ability to identify the best product for each patient.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3141e457>Non-factor therapies</h2><p class="" id=d3141e460>Novel technologies aimed at promoting hemostasis in patients with hemophilia without replacing the deficient factor are currently in clinical development. These include FVIII mimics<sup><a href="#ref-49">49</a>–<a href="#ref-52">52</a></sup> and agents that obstruct the function of natural anti-coagulants, such as antithrombin (AT)<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>, tissue factor pathway inhibitor (TFPI)<sup><a href="#ref-55">55</a>–<a href="#ref-59">59</a></sup>, and activated protein C (APC)<sup><a href="#ref-60">60</a>,<a href="#ref-61">61</a></sup>.</p><p class="" id=d3141e491>Emicizumab is a bispecific antibody that can simulate the biological function of FVIII sufficiently to produce a pro-coagulant effect in patients with HA<sup><a href="#ref-49">49</a>–<a href="#ref-52">52</a></sup>. One antigen-binding fragment (Fab) of the bispecific antibody recognizes activated FIX (FIXa), while the other Fab recognizes its substrate, factor X (FX); the simultaneous binding of FX and FIXa by emicizumab sufficiently orients these factors to facilitate the proteolytic activation of FX by FIXa without FVIIIa cofactor activity. Clinical studies have demonstrated that emicizumab is efficacious in decreasing, though not eliminating, the bleeding rate in HA patients with and without inhibitors<sup><a href="#ref-49">49</a>,<a href="#ref-51">51</a></sup>. Encouragingly, the annualized bleeding rate (ABR) of inhibitor patients receiving emicizumab prophylaxis (ABR 2.9) is lower than rates with prophylactic bypassing therapies (ABR 10–36)<sup><a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>. The rationale of targeting natural anti-coagulants is based on clinical observations<sup><a href="#ref-64">64</a>–<a href="#ref-67">67</a></sup> and animal model data<sup><a href="#ref-67">67</a>,<a href="#ref-68">68</a></sup> that demonstrate that a decrease in these anti-coagulant pathways may offset the pro-coagulant deficiency in hemophilia and promote hemostasis. Approaches with reported early phase clinical trial results include the AT siRNA therapeutic fitusiran<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup> and a monoclonal antibody directed against TFPI<sup><a href="#ref-55">55</a></sup>, concizumab; both drugs demonstrated encouraging efficacy data. The hemostatic effect of non-factor therapies (NFTs) is impervious to inhibitors. NFTs can also be administered subcutaneously at weekly to monthly frequencies, which is appealing compared to frequent intravenous administrations of standard factor products, though injection site adverse events have been reported in 15–25% of patients receiving NFTs<sup><a href="#ref-49">49</a>,<a href="#ref-54">54</a></sup>. These attributes have generated considerable excitement; however, how these new treatments will be integrated into clinical practice depends on the resolution of several ongoing debates.</p><div class=section><a name=d3141e548 class=n-a></a><h3 class=section-title>What is the risk of thrombosis from unregulated hemostasis?</h3><p class="" id=d3141e553>In normal physiology, the endogenous pro-coagulant and anti-coagulant pathways are interwoven with multiple regulatory interactions that promote hemostasis (stopping bleeding) while minimizing thrombosis (pathological clotting). NFTs exert their hemostatic effect by circumventing these regulatory interactions in order to therapeutically “rebalance” the coagulation cascade to account for the underlying bleeding disorder<sup><a href="#ref-69">69</a></sup>. However, the new balance provided by NFTs between hemostasis and thrombosis is likely not as stable as occurs in normal physiology or with targeted factor replacement. This instability is illustrated by the observation that five of the 18 patients on emicizumab prophylaxis who experienced breakthrough bleeding and required management with aPCCs developed thrombotic complications<sup><a href="#ref-49">49</a></sup>. aPCC is a concentrate of plasma-derived zymogen and activated coagulation factors that has been used for more than four decades to treat bleeding in inhibitor patients<sup><a href="#ref-70">70</a>,<a href="#ref-71">71</a></sup>. Thrombotic complications are rare (&lt;10 per 100,000 infusions) but are a well-recognized risk, especially when combined with other hemostatic therapies such as rFVIIa<sup><a href="#ref-70">70</a>,<a href="#ref-71">71</a></sup>. It is, therefore, not surprising that the thrombotic complications with emicizumab also occurred when emicizumab was combined with one or more additional bypassing agents. Nevertheless, the increased susceptibility of subjects receiving emicizumab and aPCC to thrombosis suggests a synergistic interplay<sup><a href="#ref-72">72</a>–<a href="#ref-74">74</a></sup>. aPCC contains FIXa<sup><a href="#ref-70">70</a></sup>, whose enzymatic activity is enhanced 20,000-fold by emicizumab<sup><a href="#ref-52">52</a></sup> in a biochemically unregulated manner. Emicizumab, unlike FVIII, does not require activation to exert its pro-hemostatic effect, which has been suggested to result in an earlier acceleration of coagulation<sup><a href="#ref-50">50</a></sup>. As such, there is a biochemical rationale why the concomitant use of emicizumab and aPCC may be especially prothrombotic<sup><a href="#ref-74">74</a></sup>. These thrombotic complications all occurred in emicizumab prophylaxis subjects who received &gt;100 units/kg/day of aPCC, which is within the typical dosing recommendations of aPCC (&lt;200 units/kg/day). As FIX and FX provided by aPCC have half-lives of 18 and 40 hours, respectively, the potential for accumulation due to multiple administrations raises safety concerns. To date, the risk-mitigation strategy of limiting aPCC doses below this threshold has been successful, and emicizumab was recently approved by the FDA for HA patients with inhibitors.</p><p class="" id=d3141e602>The risk of thrombotic complications due to unregulated hemostasis is not unique to emicizumab. Though no thrombotic adverse events were observed in the phase I studies, elevated D-dimer levels, a marker of pathological coagulation, were noted in several study participants receiving NFTs targeting AT<sup><a href="#ref-54">54</a></sup> and TFPI<sup><a href="#ref-55">55</a></sup>. Recently, a phase II study evaluating fitusiran was temporarily suspended after a fatal thrombotic complication<sup><a href="#ref-75">75</a></sup>. The attractive pharmacokinetic parameters of NFTs that allow for weekly to monthly dosing appear to complicate the management of breakthrough bleeding episodes, as they probably necessitate combination therapies, which will likely increase the risk of thrombotic events. How to safely combine therapies will require thoughtful consideration and empiric studies. This concern raises the question of whether hemophilia patients should be evaluated for thrombophilias prior to starting NFTs. Indeed, one of the five subjects who experienced a thrombotic complication while receiving emicizumab was heterozygous for factor V Leiden<sup><a href="#ref-49">49</a></sup>, the most common inherited thrombophilia with a prevalence of approximately 5% in the Caucasian population<sup><a href="#ref-76">76</a></sup>. It also suggests the possibility that antidotes for NFTs may be helpful in the treatment of acute bleeds, which are not available currently except for recombinant AT, which should be able to reverse fitusiran.</p></div><div class=section><a name=d3141e626 class=n-a></a><h3 class=section-title>Are NFTs “better” for all patients?</h3><p class="" id=d3141e631>The possibility of prophylactic hemostatic coverage while avoiding venipuncture is probably attractive to all patients, but it remains unclear if NFTs will demonstrate better long-term outcomes than factor products for all clinical scenarios. The concerns regarding how best to treat breakthrough bleeding in inhibitor patients receiving NFTs should frame the debate about the role of ITI once NFTs enter clinical practice. ITI is challenging for patients and families; for example, almost 20% of randomized subjects withdrew from a recent ITI clinical trial<sup><a href="#ref-77">77</a></sup>. Central venous catheters are almost always required for pediatric patients and are associated with thrombotic and infectious complications<sup><a href="#ref-77">77</a>,<a href="#ref-78">78</a></sup>. However, in the absence of inhibitors, nothing works as well to control and prevent bleeding as factor replacement<sup><a href="#ref-4">4</a></sup>. Moreover, it is unlikely that NFTs will be able to provide sufficient hemostasis for major surgery or trauma necessitating combination therapy with additional bypassing agents, which are neither as efficacious nor as safe as factor replacement. As such, despite the challenges associated with ITI, successful ITI will likely continue to provide superior long-term clinical outcomes compared to NFT prophylaxis with persistent inhibitors. Better risk stratification algorithms<sup><a href="#ref-4">4</a></sup> may identify subsets of patients who are very unlikely to tolerize with current ITI regimens, but even these patients may benefit from novel ITI strategies<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup> rather than being immediately resigned to life-long NFT prophylaxis. Whether NFT prophylaxis can be combined safely with ITI remains a critical question and requires additional studies.</p><p class="" id=d3141e660>The preliminary demonstrations of the efficacy of NFTs to prevent bleeding have raised the question of whether these agents will eventually supplant factor replacement as prophylaxis for patients without inhibitors. Current prophylactic regimens are challenging, with almost 40% of adult patients not routinely receiving prophylaxis<sup><a href="#ref-81">81</a></sup>. It has also been speculated that subcutaneous delivery of NFTs may allow for earlier initiation of prophylaxis in infants, which could delay factor exposure and potentially prevent inhibitor development<sup><a href="#ref-82">82</a></sup>. The previous attempt to test this hypothesis, that delaying factor exposure reduces inhibitors through the use of standard bypassing therapy, was unsuccessful owing to breakthrough bleeding<sup><a href="#ref-83">83</a></sup>, which may be mitigated by increased hemostatic efficacy of new NFTs. However, well-defined relationships between the number of factor exposures and the timing of inhibitor development<sup><a href="#ref-31">31</a>,<a href="#ref-84">84</a></sup> support this parameter as being the most important rather than the age of exposure; indeed, emerging evidence suggests that earlier exposure to allergens may be protective<sup><a href="#ref-85">85</a></sup>. Factor exposure in the setting of immunological “danger signals”, such as traumatic bleeds or surgery, also increases the risk of inhibitor development<sup><a href="#ref-86">86</a></sup>. As it is unlikely that NFTs will provide sufficient prophylaxis for patients never to require factor products, NFTs could potentially increase the risk by concentrating exposures to situations with immunological “danger signals”. It is possible, however, that the ease of administration of NFTs will attract patients who are currently declining prophylaxis and/or who are noncompliant.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3141e695>Clinical gene therapy</h2><p class="" id=d3141e698>Decades of collective effort on the use of adeno-associated virus (AAV) as a vector for hemophilia have culminated with recent successes in long-term expression of therapeutic FVIII and FIX levels, amelioration of the disease phenotype, and reduction or even discontinuation of factor replacement<sup><a href="#ref-87">87</a>–<a href="#ref-89">89</a></sup>. The first in-human AAV liver gene therapy for HB paved the way for the current successful strategies by showing that AAV can achieve therapeutic levels of functional FIX in a dose-dependent manner, but pre-existing neutralizing antibodies (NAb) to the AAV capsid can prevent liver transduction<sup><a href="#ref-90">90</a></sup>. These NAb are present in about 40% of the general population for some AAV serotypes<sup><a href="#ref-91">91</a></sup>. In addition, an AAV capsid-mediated cellular immune response can limit the duration of the transgene expression and is clinically recognized by an increase in liver enzymes (ALT/AST) and/or decrease in transgene expression levels<sup><a href="#ref-90">90</a>,<a href="#ref-92">92</a>–<a href="#ref-94">94</a></sup>. Subsequent trials, therefore, excluded subjects with NAb to the vector capsid and closely monitored for the capsid-directed immune response, which was managed by immunosuppression.</p><p class="" id=d3141e726>AAV is a single-stranded DNA, non-pathogenic, replication defective virus from the parvovirus family<sup><a href="#ref-92">92</a>,<a href="#ref-95">95</a></sup>. AAV vectors have a package capacity of 4.7 kb, which easily can accommodate FIX cDNA (approximately 1.6 kb)<sup><a href="#ref-96">96</a></sup> but was initially challenging for FVIII cDNA (7 kb) even after the removal of the B-domain (BDD, approximately 40% of the gene, 4.4 kb) that is not required for coagulation function<sup><a href="#ref-97">97</a></sup>. Consequently, AAV-based gene therapy strategies were initially focused on HB, despite the fact that it is the least common form of hemophilia.</p><p class="" id=d3141e744>There are several natural AAV serotypes derived from humans and non-human primates as well as synthetic capsids, which are engineered to enhance tissue tropism<sup><a href="#ref-95">95</a></sup>. All vectors tested in recent clinical trials have high tropism for the liver, which allows delivery via peripheral vein infusion. The expression of the transgene is restricted to hepatocytes by using distinct liver-specific promoters. All studies use codon optimization to enhance transgene expression levels and, in some trials, FIX variants with enhanced biological activity.</p><div class=section><a name=d3141e751 class=n-a></a><h3 class=section-title>What are the current gene therapy clinical studies for hemophilia?</h3><p class="" id=d3141e756>Results from recent early phase studies are summarized in <a href="#T1">Table 1</a>. The St Jude Children’s Research Hospital and University College of London (SJCRH/UCL) HB study using AAV-8-FIX-WT at doses of 2 × 10<sup>11</sup> to 2 × 10<sup>12</sup> vg/kg in 10 subjects demonstrated sustained FIX levels ranging from 2–5% in a dose-dependent manner reported over a 3-year period with ongoing observations<sup><a href="#ref-98">98</a>,<a href="#ref-99">99</a></sup>. The transgene is biologically functional as observed by an approximately 90% decrease in bleeding episodes in the high-dose cohort. However, four out of six subjects presented with increased levels of ALT between weeks 7 and 10 post-vector injection, with some decrease in the FIX levels suggestive of AAV-mediated cellular immune responses. Administration of oral steroids prevented total loss of FIX expression, but prompt (&lt;48 hours) initiation of the drug provided the best outcome. No immune responses were observed in doses ≤6 × 10<sup>11</sup> vg/kg (n=4). In an ongoing study by Spark, an AAV-FIX variant (FIX-Padua) at a low therapeutic dose of 5 × 10<sup>11</sup> vg/kg was delivered to 10 subjects<sup><a href="#ref-100">100</a></sup>. The hyperactive FIX-Padua is a protein with approximately eightfold higher specific activity<sup><a href="#ref-101">101</a></sup>. Thus, it was anticipated that therapeutic levels of FIX could be achieved at a dose fourfold lower than was previously associated with AAV-mediated cellular immune responses in the AAV-8<sup><a href="#ref-98">98</a>,<a href="#ref-99">99</a>,<a href="#ref-102">102</a></sup> and AAV-2<sup><a href="#ref-90">90</a></sup> trials. FIX activity reached levels of 30% without inhibitor formation to FIX-Padua, and prophylaxis with FIX concentrates was stopped in all subjects for a ≥3-month period; long-term follow-up is ongoing. Notably, the rate of immune responses to AAV was lower, as only two out of 10 subjects required immunosuppression. These results demonstrate that FIX-Padua is safe and allows therapeutic levels with a lower risk of vector capsid immune responses. Evidence of FIX-Padua as an attractive transgene was also observed in a previous study by Shire using AAV-8 for HB<sup><a href="#ref-103">103</a>,<a href="#ref-104">104</a></sup>. Long-term expression was restricted to a single subject (1 × 10<sup>12</sup> vg/kg) with FIX activity of 20%. In this study, immunosuppression was not effective at preventing the loss of transgene expression. Again, no inhibitors to FIX-Padua were detected, as was predicted in large animal models<sup><a href="#ref-105">105</a>,<a href="#ref-106">106</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Summary of recently reported AAV gene therapy trial results.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d3141e833 class=n-a></a><thead><a name=d3141e835 class=n-a></a><tr><a name=d3141e837 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d3141e839 class=n-a></a>Sponsor</th><th align=center colspan=1 rowspan=1><a name=d3141e842 class=n-a></a>Hemophilia</th><th align=center colspan=1 rowspan=1><a name=d3141e845 class=n-a></a>Vector</th><th align=center colspan=1 rowspan=1><a name=d3141e848 class=n-a></a>Manufacturing</th><th align=center colspan=1 rowspan=1><a name=d3141e851 class=n-a></a>Dose (vg/kg)</th><th align=center colspan=1 rowspan=1><a name=d3141e855 class=n-a></a>Liver<br class=br>enzyme<br class=br>elevation<a href="#fn2">†</a></th><th align=center colspan=1 rowspan=1><a name=d3141e864 class=n-a></a>Effective<br class=br>immuno-<br class=br>suppression?</th><th align=center colspan=1 rowspan=1><a name=d3141e871 class=n-a></a>Transgene<br class=br>expression<br class=br>(% normal)</th><th align=center colspan=1 rowspan=1><a name=d3141e878 class=n-a></a>Ref.</th></tr></thead><tbody><a name=d3141e883 class=n-a></a><tr><a name=d3141e885 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d3141e887 class=n-a></a> <b>SJCRH/UCL</b> </td><td align=center colspan=1 rowspan=1><a name=d3141e893 class=n-a></a>HB</td><td align=center colspan=1 rowspan=1><a name=d3141e896 class=n-a></a>AAV8-FIX-WT</td><td align=center colspan=1 rowspan=1><a name=d3141e899 class=n-a></a>Plasmid DNA/<br class=br>mammalian cell<br class=br>line</td><td align=center colspan=1 rowspan=1><a name=d3141e906 class=n-a></a>2 × 10<sup>11</sup> – 2 × 10<sup>12</sup></td><td align=center colspan=1 rowspan=1><a name=d3141e915 class=n-a></a>4/6</td><td align=center colspan=1 rowspan=1><a name=d3141e918 class=n-a></a>Yes</td><td align=center colspan=1 rowspan=1><a name=d3141e921 class=n-a></a>2–5%</td><td align=center colspan=1 rowspan=1><a name=d3141e924 class=n-a></a><a href="#ref-98">98</a>,<a href="#ref-99">99</a></td></tr><tr><a name=d3141e932 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d3141e934 class=n-a></a> <b>Spark</b> </td><td align=center colspan=1 rowspan=1><a name=d3141e940 class=n-a></a>HB</td><td align=center colspan=1 rowspan=1><a name=d3141e943 class=n-a></a>SPK100-FIX-<br class=br>Padua</td><td align=center colspan=1 rowspan=1><a name=d3141e948 class=n-a></a>Plasmid DNA/<br class=br>mammalian cell<br class=br>line</td><td align=center colspan=1 rowspan=1><a name=d3141e955 class=n-a></a>5 × 10<sup>11</sup></td><td align=center colspan=1 rowspan=1><a name=d3141e961 class=n-a></a>2/10</td><td align=center colspan=1 rowspan=1><a name=d3141e964 class=n-a></a>Yes</td><td align=center colspan=1 rowspan=1><a name=d3141e967 class=n-a></a>~30%</td><td align=center colspan=1 rowspan=1><a name=d3141e970 class=n-a></a><a href="#ref-100">100</a></td></tr><tr><a name=d3141e975 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d3141e977 class=n-a></a> <b>Shire</b> </td><td align=center colspan=1 rowspan=1><a name=d3141e983 class=n-a></a>HB</td><td align=center colspan=1 rowspan=1><a name=d3141e986 class=n-a></a>AAV8-FIX-<br class=br>Padua</td><td align=center colspan=1 rowspan=1><a name=d3141e991 class=n-a></a>Plasmid DNA/<br class=br>mammalian cell<br class=br>line</td><td align=center colspan=1 rowspan=1><a name=d3141e998 class=n-a></a>2 × 10<sup>11</sup> – 3 × 10<sup>12</sup></td><td align=center colspan=1 rowspan=1><a name=d3141e1007 class=n-a></a>NR</td><td align=center colspan=1 rowspan=1><a name=d3141e1010 class=n-a></a>No</td><td align=center colspan=1 rowspan=1><a name=d3141e1013 class=n-a></a>0–20%</td><td align=center colspan=1 rowspan=1><a name=d3141e1016 class=n-a></a><a href="#ref-107">107</a>,<a href="#ref-108">108</a></td></tr><tr><a name=d3141e1024 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d3141e1026 class=n-a></a> <b>uniQure</b> </td><td align=center colspan=1 rowspan=1><a name=d3141e1032 class=n-a></a>HB</td><td align=center colspan=1 rowspan=1><a name=d3141e1035 class=n-a></a>AAV5-FIX-WT</td><td align=center colspan=1 rowspan=1><a name=d3141e1038 class=n-a></a>Baculovirus/<br class=br>insect cell line</td><td align=center colspan=1 rowspan=1><a name=d3141e1043 class=n-a></a>5 × 10<sup>12</sup> – 2 × 10<sup>13</sup></td><td align=center colspan=1 rowspan=1><a name=d3141e1052 class=n-a></a>2/5</td><td align=center colspan=1 rowspan=1><a name=d3141e1055 class=n-a></a>Yes</td><td align=center colspan=1 rowspan=1><a name=d3141e1058 class=n-a></a>3–12%</td><td align=center colspan=1 rowspan=1><a name=d3141e1061 class=n-a></a><a href="#ref-102">102</a></td></tr><tr><a name=d3141e1066 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d3141e1068 class=n-a></a> <b>Biomarin</b> </td><td align=center colspan=1 rowspan=1><a name=d3141e1074 class=n-a></a>HA</td><td align=center colspan=1 rowspan=1><a name=d3141e1077 class=n-a></a>AAV5-BDD-<br class=br>FVIII</td><td align=center colspan=1 rowspan=1><a name=d3141e1082 class=n-a></a>Baculovirus/<br class=br>insect cell line</td><td align=center colspan=1 rowspan=1><a name=d3141e1087 class=n-a></a>6 × 10<sup>12</sup> – 6 × 10<sup>13</sup></td><td align=center colspan=1 rowspan=1><a name=d3141e1096 class=n-a></a>7/7</td><td align=center colspan=1 rowspan=1><a name=d3141e1099 class=n-a></a>Yes</td><td align=center colspan=1 rowspan=1><a name=d3141e1102 class=n-a></a>19–164%</td><td align=center colspan=1 rowspan=1><a name=d3141e1105 class=n-a></a><a href="#ref-109">109</a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=fn1 class=n-a></a><p id=d3141e1116><span class=warning></span> Abbreviations: AAV, adeno-associated virus; HA, hemophilia A; HB, hemophilia B; NR, not reported; Ref., reference; SJCRH/UCL, St Jude Children’s Research Hospital/University College of London; BDD, B-domain deleted.</p></div><div class=footnote><a name=fn2 class=n-a></a><p id=d3141e1125>† (Number of subjects in highest-dose cohort who experienced increased alanine aminotransferase)/(number of subjects in highest-dose cohort)</p></div></div></div><p class="" id=d3141e1131>The uniQure study for HB is based on AAV-5-FIX-WT at doses of 5 × 10<sup>12</sup> to 2 × 10<sup>13</sup> vg/kg with resulting FIX levels ranging from 3–12% and nine out of 10 subjects stopped prophylaxis over 1.5 years of observation (ongoing)<sup><a href="#ref-102">102</a></sup>. However, there was not a clear dose response. An increase in ALT levels occurred in three out of 10 subjects around 10 weeks post AAV injection; all three subjects received steroids and none experienced appreciable FIX activity loss. The HA Biomarin study is based on AAV-5-BDD-FVIII. In the high-dose cohort (6 × 10<sup>13</sup> vg/kg), sustained expression of FVIII of 19–164% of normal over a 12-month period was a rather surprising finding (ongoing)<sup><a href="#ref-109">109</a></sup>. All subjects are off prophylaxis. While an increase in ALT was documented in all subjects from this cohort, and steroids were initiated in all, there was not a clear relationship among ALT normalization, steroid use, and FVIII level stabilization. An additional safety concern raised by the AAV-5 trials is prolonged vector shedding in body fluids, including semen, where samples tested positive for vector sequences for 48 and 52 weeks (yet not cleared) post vector delivery at doses of 5 × 10<sup>12</sup> vg/kg and 6 × 10<sup>13</sup> vg/kg in FIX and FVIII trials, respectively. It is also important to note that age may also influence the vector shedding kinetics from the semen<sup><a href="#ref-90">90</a>,<a href="#ref-110">110</a></sup>. Results from other clinical trials have not been reported.</p></div><div class=section><a name=d3141e1167 class=n-a></a><h3 class=section-title>What should be a feasible and safe therapeutic range?</h3><p class="" id=d3141e1172>In the early days of gene therapy, the goal was rather modest: minimal increase of factor levels above 1% could improve the severe phenotype, as noted by both natural history of non-severe disease and prophylaxis. However, in a trial with two subjects with advanced underlying joint disease, FIX levels of 1.5–3% were not sufficient to prevent bleeds, and prophylaxis was continued<sup><a href="#ref-98">98</a>,<a href="#ref-99">99</a></sup>. Thus, strategies with the potential to achieve &gt;5% of normal are likely to be more effective, with some evidence that levels above 12% could be associated with no spontaneous bleeding<sup><a href="#ref-111">111</a></sup>. This is rather challenging for those with advanced joint disease who are likely to require surgical intervention despite these therapeutic levels.</p><p class="" id=d3141e1186>In the general population, increased levels of FVIII or FIX are associated with increased risk of thrombosis<sup><a href="#ref-112">112</a>–<a href="#ref-117">117</a></sup>. Supraphysiological levels of FVIII in the HA study raise safety concerns<sup><a href="#ref-114">114</a>,<a href="#ref-115">115</a>,<a href="#ref-118">118</a></sup>, since men with hemophilia are not protected from cardiovascular disease and remain at risk of thrombotic complications<sup><a href="#ref-118">118</a></sup>. In addition, there is no evidence that levels above 50% of normal are associated with pathological bleeding, and hemophilia carriers have decreased mortality due to ischemic heart disease<sup><a href="#ref-119">119</a></sup>. The relative short-term follow-up of HA patients expressing elevated levels of FVIII prevent firm conclusions on the safety of this finding.</p></div><div class=section><a name=d3141e1215 class=n-a></a><h3 class=section-title>Is codon optimization of the transgene safe?</h3><p class="" id=d3141e1220>Codon optimization uses synonymous codon changes to increase protein expression without modifying amino acid sequences. The development of numerous codon optimization programs and the commercial availability make this strategy popular. However, there are potential risks, such as the creation of alternative open reading frames and alteration in protein post-translational modifications<sup><a href="#ref-120">120</a></sup>. As such, for codon optimization, the benefits in gain of expression must be weighed against these safety concerns. To date, the biochemical characterization of a codon-optimized FVIII-BDD that is expressed sevenfold higher than the non-codon-optimized FVIII showed similar, but not identical, biological activity<sup><a href="#ref-121">121</a></sup>. The transgene used in these studies is the same as that used in the current HA trial by Biomarin<sup><a href="#ref-122">122</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3141e1239>AAV capsid-mediated T cell responses</h2><p class="" id=d3141e1242>The most common short-term safety concern of AAV gene therapy is the generation of AAV capsid-mediated cellular responses<sup><a href="#ref-90">90</a>,<a href="#ref-92">92</a>–<a href="#ref-94">94</a></sup>. This complication is restricted to humans, as provocative preclinical studies in small and large animals failed to fully replicate the clinical findings. Encouragingly, this absence of AAV capsid-mediated cellular responses in hemophiliac dogs has resulted in &gt;8 years of sustained expression<sup><a href="#ref-123">123</a></sup> and created an opportunity for providing a relatively low-risk treatment to HA pet dogs<sup><a href="#ref-124">124</a></sup>. In humans, the need for rapid initiation of the immunosuppression therapy to prevent total loss of expression requires a close monitoring of the subjects, which imposes challenging clinical care as studies move beyond early phases. It is not possible to currently identify those who will develop such complications, but some clinical strategies may help to overcome it.</p><div class=section><a name=d3141e1263 class=n-a></a><h3 class=section-title>What are the clinical factors triggering immune response to the vector capsid?</h3><p class="" id=d3141e1268>Data from clinical studies show that capsid-mediated immune responses occur with all serotypes in a vector dose-dependent manner. The onset and dose dependence varies among distinct serotypes. For example, in AAV-2 and AAV-8, the dose of 2 × 10<sup>12</sup> vg/kg<sup><a href="#ref-90">90</a>,<a href="#ref-99">99</a>,<a href="#ref-100">100</a></sup> was the threshold for immune responses, whereas for AAV-5 in one study for HB<sup><a href="#ref-102">102</a>,<a href="#ref-106">106</a></sup> the dose was 5–10-fold higher. Interestingly, in a study using AAV-5 for HA<sup><a href="#ref-105">105</a>,<a href="#ref-109">109</a>,<a href="#ref-110">110</a></sup>, only at doses of 6 × 10<sup>13</sup> vg/kg (30-fold higher than AAV-2 and AAV-8 cited above) were immune responses noted. The initial mechanism of elevation of liver enzymes in the trials using AAV-5 was thought to be due to AAV-capsid immune responses. However, in both studies, the dose-dependent increase in liver enzymes was not associated with detectable T cell expansion. Nevertheless, transient immunosuppression was initiated and liver enzymes normalized. The underlying mechanism of this complication is unclear at this point and may be a direct effect of the vector on the hepatocytes. Therefore, this may influence the long-term safety profile of AAV-5. One possibility for these discrepancies is that AAV-5 vectors were produced using a baculovirus system with insect cells lines, whereas, for the other serotypes, plasmid systems in mammalian cell lines were used. It is known that AAV-5 production in insect cell lines resulted in low infectivity per particle; thus, higher therapeutic vector doses were anticipated<sup><a href="#ref-125">125</a>–<a href="#ref-127">127</a></sup>. Thus, the emerging data suggest that the vector manufacturing process may also influence the safety profile of AAV. To date, a side-by-side comparison of AAV biological activity using distinct manufacturing systems is lacking. Differences in dose needed for therapeutic transgene expression between vectors may account for increased concentration of capsid that is presented to hepatocytes, leading to stimulation of memory T cells.</p></div><div class=section><a name=d3141e1313 class=n-a></a><h3 class=section-title>Is lowering the therapeutic vector dose the safest strategy to avoid immune responses?</h3><p class="" id=d3141e1318>The study using AAV-Spark100-FIX-Padua at 5 × 10<sup>11</sup> vg/kg resulted in sustained therapeutic levels of FIX of approximately 30%<sup><a href="#ref-128">128</a></sup>. Immune responses triggered by AAV capsid occurred in only two out of 10 subjects. In contrast, in the study using AAV-8-FIX-WT at 2 × 10<sup>12</sup> vg/kg (fourfold higher dose), four out of six subjects developed these immune responses<sup><a href="#ref-99">99</a></sup>. Thus, the use of a transgene with enhanced biological activity allows an effective and safe strategy by minimizing vector-mediated cellular responses. This is also attractive since the AAV-5 trials showed that there is a dose-dependent elevation of the liver enzymes; thus, lowering the therapeutic dose would likely benefit all future studies.</p></div><div class=section><a name=d3141e1336 class=n-a></a><h3 class=section-title>Is CpG content a risk factor for immune responses to the vector capsid?</h3><p class="" id=d3141e1341>Preclinical studies suggest that activation of innate immune responses through CpG-mediated Toll-like receptor 9 was a potential underlying mechanism for the stimulation of AAV capsid-mediated CD8<sup>+</sup> T cell cytotoxicity. The use of CpG-depleted codon-optimized FIX transgene in preclinical models was aimed at high expression level<sup><a href="#ref-129">129</a></sup>. Notably, the first AAV liver trial using the same FIX transgene resulted in AAV capsid-mediated immune response in four out of six subjects in the high-dose cohort<sup><a href="#ref-99">99</a></sup>. It is, therefore, probable that the innate immune responses may differ between humans and other species and that simply removing CpGs will not prevent vector capsid immune responses in patients, though the role of the innate immune response in the anti-AAV capsid cellular immune response deserves continued study<sup><a href="#ref-130">130</a></sup>. Data on the CpG content of the other vectors have not been published.</p></div><div class=section><a name=d3141e1361 class=n-a></a><h3 class=section-title>Is transient immunosuppression enough?</h3><p class="" id=d3141e1366>The hepatocyte toxicity triggered by AAV capsid immune responses is clinically asymptomatic and resembles, to a certain extent, autoimmune hepatitis<sup><a href="#ref-131">131</a></sup>. As such, the use of steroids as the first line of treatment is reasonable. Data suggest that steroids are most effective if initiated within 48 hours after increase of liver enzymes and/or decrease in transgene expression and should be continued for 8–12 weeks<sup><a href="#ref-99">99</a>,<a href="#ref-128">128</a></sup>. This strategy has been effective in most studies. However, in the Shire-sponsored study, therapeutic levels of FIX (peak at 60%) were achieved in the high-dose cohort (3 × 10<sup>12</sup> vg/kg), but the duration of expression was transient and reduction in expression coincided with increased ALT<sup><a href="#ref-103">103</a></sup>. In an AAV-8-FIX clinical study at the Children’s Hospital of Philadelphia, three subjects were infused at doses of 1 to 2 × 10<sup>12</sup> vg/kg and all developed an immune response to the vector capsid that was not controlled by immunosuppression, resulting in loss of transgene expression<sup><a href="#ref-94">94</a></sup>. Alternative immunosuppression regimens may be required<sup><a href="#ref-132">132</a></sup>.</p><p class="" id=d3141e1399>Whether preventive therapy with steroids would be a more manageable strategy is complicated by the fact that timing of the immune response ranges from 4–10 weeks post vector delivery and depends on the vector serotype. However, it seems that, for a given serotype, the time of immune response onset is very consistent. Thus, if one subject developed immune responses, all subsequent subjects in the same dose cohort could receive prophylactic immunosuppression.</p><p class="" id=d3141e1402>The reasons why immunosuppression can overcome immune response to the vector capsid in some, but not all, studies is unclear. It is possible that the combination of vector design (codon optimization/CpG content), the ratio of empty and full capsid particles, host-dependent factors such as HLA, and the innate ability to mount cellular immune responses could all contribute. Hopefully, as these vector systems and clinical outcomes will be further characterized in future publications, we will likely have more insights on this safety concern.</p></div><div class=section><a name=d3141e1406 class=n-a></a><h3 class=section-title>Is there a risk of inhibitor formation to the transgene product?</h3><p class="" id=d3141e1411>As for any other novel therapy for hemophilia, there are concerns regarding the risk of inhibitor formation. To date, the presence or history of inhibitors and minimal exposure to factor concentrates are exclusion criteria in all of these studies. However, preclinical studies in small and large models showed that AAV liver-restricted expression is biased towards transgene-specific immune tolerance<sup><a href="#ref-80">80</a>,<a href="#ref-133">133</a></sup>. Moreover, in hemophiliac dogs with inhibitor to FVIII or FIX, AAV expression of the transgene was efficacious in inhibitor eradication, mimicking ITI, followed by continuing expression with improvement of the disease phenotype<sup><a href="#ref-80">80</a>,<a href="#ref-105">105</a>,<a href="#ref-134">134</a></sup>.</p></div><div class=section><a name=d3141e1432 class=n-a></a><h3 class=section-title>Which strategy is better?</h3><p class="" id=d3141e1437>With growing numbers of clinical studies using diverse strategies, one important issue is to define a superior approach. The simplest outcome measurement, such as sustained factor levels, is a logical criterion. However, if a very high vector dose is needed to achieve high therapeutic levels, the impact on the vector manufacturing to a large patient population may be hampered by production feasibility issues and raises safety concerns. Another possibility is that of a strategy with minimal or no risk of vector-mediated immune responses yet with factor levels in the mild disease range. This could bring the benefits of prophylaxis to a large population without the time-consuming and labor-intensive monitoring of ALT and factor levels. Preventive immunosuppression could simplify this process, but, as discussed above, it is not always feasible. Furthermore, the lack of normalization on the strategy used to define the vector genome prevents direct comparison among distinct vectors<sup><a href="#ref-135">135</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3141e1449>Closing paragraph</h2><p class="" id=d3141e1452>These new therapies will likely transform hemophilia care, providing more efficacious and convenient management options and possibly curative therapies. The largest gains will be accrued by those patients receiving only limited therapeutic benefits from current strategies, such as those with refractory inhibitors and frequent bleeding. However, it is imperative that the excitement over the considerable potential of these drugs to help undertreated patients does not obscure early safety concerns such as potential pathological PEG accumulation, thrombotic complications in NFTs, and irreversible supraphysiological factor levels after gene therapy. Furthermore, the cost of these emerging therapies is not clear; whether these new strategies will expand access to the 80% of worldwide patients who are currently not receiving regular therapy for economic reasons remains unknown. Hemophilia treaters will have to balance efficacy, convenience, price, and patient preferences and lifestyle when developing personalized treatment plans that include these novel therapies. The hemophilia community is entitled to definitive answers to these questions, which will require careful preclinical and clinical studies. As the types of available therapies become more varied, such studies must include assessments of the quality of life (QoL) of patients. The ultimate goal of therapies for hemophilia is to provide a QoL and life expectancy equivalent to those of someone without a bleeding disorder.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d3141e1 class=n-a></a><h2 class=main-title id=d3530>Competing interests</h2><p class=metadata-entry><a name=d3141e127 class=n-a></a><p id=d3141e128> BSJ is an investigator on AAV gene therapy clinical trials for hemophilia sponsored by Spark Therapeutics. VRA and BSD declare that they have no competing interests.</p></p></div><div class=back-section><a name=d3141e1 class=n-a></a><h2 class=main-title id=d3532>Grant information</h2><p>VRA is supported by 1R01HL137335 from NHLBI/NIH.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript</i>.</p></div><div class=back-section><a name=d3141e1459 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d3955>References</h2><div class="section ref-list"><a name=d3141e1459 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d3141e1466 class=n-a></a>Johnson KA, Zhou ZY: Costs of care in hemophilia and possible implications of health care reform. <i>Hematology Am Soc Hematol Educ Program.</i> 2011; <b>2011</b>(1): 413–8. <a target=xrefwindow id=d3141e1474 href="http://www.ncbi.nlm.nih.gov/pubmed/22160067">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1477 href="http://dx.doi.org/10.1182/asheducation-2011.1.413">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d3141e1486 class=n-a></a>Key NS: Inhibitors in congenital coagulation disorders. <i>Br J Haematol.</i> 2004; <b>127</b>(4): 379–91. <a target=xrefwindow id=d3141e1494 href="http://www.ncbi.nlm.nih.gov/pubmed/15521914">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1497 href="http://dx.doi.org/10.1111/j.1365-2141.2004.05168.x">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d3141e1506 class=n-a></a>Laros-van Gorkom BA, Falaise C, Astermark J: Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature review. <i>Eur J Haematol Suppl.</i> 2014; <b>76</b>: 26–38. <a target=xrefwindow id=d3141e1514 href="http://www.ncbi.nlm.nih.gov/pubmed/24957105">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1517 href="http://dx.doi.org/10.1111/ejh.12372">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d3141e1526 class=n-a></a>Kempton CL, Meeks SL: Toward optimal therapy for inhibitors in hemophilia. <i>Blood.</i> 2014; <b>124</b>(23): 3365–72. <a target=xrefwindow id=d3141e1534 href="http://www.ncbi.nlm.nih.gov/pubmed/25428222">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1537 href="http://dx.doi.org/10.1182/blood-2014-05-577643">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d3141e1546 class=n-a></a>Morfini M: Pharmacokinetics of factor VIII and factor IX. <i>Haemophilia.</i> 2003; <b>9 Suppl 1</b>: 94–9; discussion 100. <a target=xrefwindow id=d3141e1554 href="http://www.ncbi.nlm.nih.gov/pubmed/12709044">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1557 href="http://dx.doi.org/10.1046/j.1365-2516.9.s1.8.x">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d3141e1567 class=n-a></a>Mannucci PM: Half-life extension technologies for haemostatic agents. <i>Thromb Haemost.</i> 2015; <b>113</b>(1): 165–76. <a target=xrefwindow id=d3141e1575 href="http://www.ncbi.nlm.nih.gov/pubmed/25274414">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1578 href="http://dx.doi.org/10.1160/TH14-04-0332">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d3141e1587 class=n-a></a>Strohl WR: Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. <i>BioDrugs.</i> 2015; <b>29</b>(4): 215–39. <a target=xrefwindow id=d3141e1595 href="http://www.ncbi.nlm.nih.gov/pubmed/26177629">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1598 href="http://dx.doi.org/10.1007/s40259-015-0133-6">Publisher Full Text </a> | <a target=xrefwindow id=d3141e1601 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4562006">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d3141e1610 class=n-a></a>Ivens IA, Baumann A, McDonald TA, <i> et al.</i>: PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. <i>Haemophilia.</i> 2013; <b>19</b>(1): 11–20. <a target=xrefwindow id=d3141e1621 href="http://www.ncbi.nlm.nih.gov/pubmed/22913770">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1624 href="http://dx.doi.org/10.1111/j.1365-2516.2012.02931.x">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726070117"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e1633 class=n-a></a>Santagostino E, Martinowitz U, Lissitchkov T, <i> et al.</i>: Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. <i>Blood.</i> 2016; <b>127</b>(14): 1761–9. <a target=xrefwindow id=d3141e1644 href="http://www.ncbi.nlm.nih.gov/pubmed/26755710">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1647 href="http://dx.doi.org/10.1182/blood-2015-09-669234">Publisher Full Text </a> | <a target=xrefwindow id=d3141e1651 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4825413">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726070117">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726331501"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e1664 class=n-a></a>Young G, Collins PW, Colberg T, <i> et al.</i>: Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). <i>Thromb Res.</i> 2016; <b>141</b>: 69–76. <a target=xrefwindow id=d3141e1675 href="http://www.ncbi.nlm.nih.gov/pubmed/26970716">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1678 href="http://dx.doi.org/10.1016/j.thromres.2016.02.030">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726331501">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d3141e1691 class=n-a></a>Konkle BA, Stasyshyn O, Chowdary P, <i> et al.</i>: Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. <i>Blood.</i> 2015; <b>126</b>(9): 1078–85. <a target=xrefwindow id=d3141e1702 href="http://www.ncbi.nlm.nih.gov/pubmed/26157075">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1705 href="http://dx.doi.org/10.1182/blood-2015-03-630897">Publisher Full Text </a> | <a target=xrefwindow id=d3141e1709 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4551361">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727123129"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e1719 class=n-a></a>Reding MT, Ng HJ, Poulsen LH, <i> et al.</i>: Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. <i>J Thromb Haemost.</i> 2017; <b>15</b>(3): 411–9. <a target=xrefwindow id=d3141e1730 href="http://www.ncbi.nlm.nih.gov/pubmed/27992112">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1733 href="http://dx.doi.org/10.1111/jth.13597">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727123129">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d3141e1746 class=n-a></a>Mahlangu J, Powell JS, Ragni MV, <i> et al.</i>: Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. <i>Blood.</i> 2014; <b>123</b>(3): 317–25. <a target=xrefwindow id=d3141e1757 href="http://www.ncbi.nlm.nih.gov/pubmed/24227821">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1760 href="http://dx.doi.org/10.1182/blood-2013-10-529974">Publisher Full Text </a> | <a target=xrefwindow id=d3141e1764 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3894491">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d3141e1773 class=n-a></a>Pipe SW, Montgomery RR, Pratt KP, <i> et al.</i>: Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. <i>Blood.</i> 2016; <b>128</b>(16): 2007–16. <a target=xrefwindow id=d3141e1784 href="http://www.ncbi.nlm.nih.gov/pubmed/27587878">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1787 href="http://dx.doi.org/10.1182/blood-2016-04-713289">Publisher Full Text </a> | <a target=xrefwindow id=d3141e1791 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5073181">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d3141e1800 class=n-a></a>Chiu PL, Bou-Assaf GM, Chhabra ES, <i> et al.</i>: Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry. <i>Blood.</i> 2015; <b>126</b>(8): 935–8. <a target=xrefwindow id=d3141e1811 href="http://www.ncbi.nlm.nih.gov/pubmed/26065652">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1814 href="http://dx.doi.org/10.1182/blood-2015-04-641688">Publisher Full Text </a> | <a target=xrefwindow id=d3141e1818 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4543227">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d3141e1827 class=n-a></a>Yee A, Oleskie AN, Dosey AM, <i> et al.</i>: Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII. <i>Blood.</i> 2015; <b>126</b>(8): 939–42. <a target=xrefwindow id=d3141e1838 href="http://www.ncbi.nlm.nih.gov/pubmed/26065653">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1841 href="http://dx.doi.org/10.1182/blood-2015-04-641696">Publisher Full Text </a> | <a target=xrefwindow id=d3141e1845 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4543228">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d3141e1854 class=n-a></a>Pestel S, Raquet E, Mischnik M, <i> et al.</i>: Half-life Extension of FVIII by Coadministration of a Recombinant D'D3 Albumin Fusion Protein. Paper presented at: Congress of the International Society of Thrombosis and Haemostasis 2017; Berlin, Germany. </span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d3141e1867 class=n-a></a>Chia J, Glauser I, Andrews A, <i> et al.</i>: FcRn Mediated Recycling of Recombinant VWF D'D3-albumin Fusion Protein/rVIII-SingleChain Complex Is a Mechanism for FVIII Half-life Extension. Paper presented at: Congress of the International Society of Thrombosis and Haemostasis 2017; Berlin, Germany. </span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731958364"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e1879 class=n-a></a>Quon DV, Klamroth R, Kulkarni R, <i> et al.</i>: Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies. <i>Haemophilia.</i> 2017; <b>23</b>(1): e39–e42. <a target=xrefwindow id=d3141e1890 href="http://www.ncbi.nlm.nih.gov/pubmed/27943467">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1893 href="http://dx.doi.org/10.1111/hae.13125">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731958364">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732291460"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e1906 class=n-a></a>Oldenburg J, Kulkarni R, Srivastava A, <i> et al.</i>: Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. <i>Haemophilia.</i> 2018; <b>24</b>(1): 77–84. <a target=xrefwindow id=d3141e1917 href="http://www.ncbi.nlm.nih.gov/pubmed/29082639">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1920 href="http://dx.doi.org/10.1111/hae.13353">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732291460">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727073882"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e1933 class=n-a></a>Giangrande P, Andreeva T, Chowdary P, <i> et al.</i>: Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. <i>Thromb Haemost.</i> 2017; <b>117</b>(2): 252–61. <a target=xrefwindow id=d3141e1944 href="http://www.ncbi.nlm.nih.gov/pubmed/27904904">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1947 href="http://dx.doi.org/10.1160/th16-06-0444">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727073882">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733031465"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e1960 class=n-a></a>Malec LM, Journeycake J, Ragni MV: Extended half-life factor VIII for immune tolerance induction in haemophilia. <i>Haemophilia.</i> 2016; <b>22</b>(6): e552–e4. <a target=xrefwindow id=d3141e1968 href="http://www.ncbi.nlm.nih.gov/pubmed/27640873">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1971 href="http://dx.doi.org/10.1111/hae.13064">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733031465">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726061363"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e1984 class=n-a></a>Groomes CL, Gianferante DM, Crouch GD, <i> et al.</i>: Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein. <i>Pediatr Blood Cancer.</i> 2016; <b>63</b>(5): 922–4. <a target=xrefwindow id=d3141e1995 href="http://www.ncbi.nlm.nih.gov/pubmed/26739399">PubMed Abstract </a> | <a target=xrefwindow id=d3141e1998 href="http://dx.doi.org/10.1002/pbc.25874">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726061363">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d3141e2012 class=n-a></a>Carcao M, Shapiro A, Staber JM, <i> et al.</i>: Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis. <i>Haemophilia.</i> 2018; <b>24</b>(2): 245–252. <a target=xrefwindow id=d3141e2023 href="http://www.ncbi.nlm.nih.gov/pubmed/29436077">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2026 href="http://dx.doi.org/10.1111/hae.13413">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d3141e2035 class=n-a></a>Pipe SW: New therapies for hemophilia. <i>Hematology Am Soc Hematol Educ Program.</i> 2016; <b>2016</b>(1): 650–6. <a target=xrefwindow id=d3141e2043 href="http://www.ncbi.nlm.nih.gov/pubmed/27913542">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2046 href="http://dx.doi.org/10.1182/asheducation-2016.1.650">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733012686"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2055 class=n-a></a>Krishnamoorthy S, Liu T, Drager D, <i> et al.</i>: Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. <i>Cell Immunol.</i> 2016; <b>301</b>: 30–9. <a target=xrefwindow id=d3141e2066 href="http://www.ncbi.nlm.nih.gov/pubmed/26775174">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2069 href="http://dx.doi.org/10.1016/j.cellimm.2015.12.008">Publisher Full Text </a> | <a target=xrefwindow id=d3141e2073 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4936482">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733012686">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d3141e2086 class=n-a></a>Lentz SR, Ehrenforth S, Karim FA, <i> et al.</i>: Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. <i>J Thromb Haemost.</i> 2014; <b>12</b>(8): 1244–53. <a target=xrefwindow id=d3141e2097 href="http://www.ncbi.nlm.nih.gov/pubmed/24931322">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2100 href="http://dx.doi.org/10.1111/jth.12634">Publisher Full Text </a> | <a target=xrefwindow id=d3141e2104 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4238784">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729718608"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2113 class=n-a></a>Mahlangu J, Paz P, Hardtke M, <i> et al.</i>: TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. <i>Haemophilia.</i> 2016; <b>22</b>(6): 873–9. <a target=xrefwindow id=d3141e2124 href="http://www.ncbi.nlm.nih.gov/pubmed/27501279">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2127 href="http://dx.doi.org/10.1111/hae.12994">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729718608">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727200838"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2140 class=n-a></a>Lamberth K, Reedtz-Runge SL, Simon J, <i> et al.</i>: Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. <i>Sci Transl Med.</i> 2017; <b>9</b>(372): pii: eaag1286. <a target=xrefwindow id=d3141e2151 href="http://www.ncbi.nlm.nih.gov/pubmed/28077675">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2154 href="http://dx.doi.org/10.1126/scitranslmed.aag1286">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727200838">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d3141e2168 class=n-a></a>Commitee BPA: BPAC Briefing Document: BLA 125611, Coagulation Factor IX (Recombinant), GlycoPEGylated. In Administration FaD, ed. Washington, D.C. 2017; 1–24. <a target=xrefwindow id=d3141e2170 href="https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM549857.pdf">Reference Source</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d3141e2179 class=n-a></a>Gouw SC, van der Bom JG, Marijke van den Berg H: Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. <i>Blood.</i> 2007; <b>109</b>(11): 4648–54. <a target=xrefwindow id=d3141e2187 href="http://www.ncbi.nlm.nih.gov/pubmed/17289808">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2190 href="http://dx.doi.org/10.1182/blood-2006-11-056291">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d3141e2199 class=n-a></a>Peerlinck K, Arnout J, Gilles JG, <i> et al.</i>: A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. <i>Thromb Haemost.</i> 1993; <b>69</b>(2): 115–8. <a target=xrefwindow id=d3141e2210 href="http://www.ncbi.nlm.nih.gov/pubmed/8456422">PubMed Abstract </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d3141e2219 class=n-a></a>Rosendaal FR, Nieuwenhuis HK, van den Berg HM, <i> et al.</i>: A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. <i>Blood.</i> 1993; <b>81</b>(8): 2180–6. <a target=xrefwindow id=d3141e2230 href="http://www.ncbi.nlm.nih.gov/pubmed/8471777">PubMed Abstract </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d3141e2239 class=n-a></a>White GC 2nd, Courter S, Bray GL, <i> et al.</i>: A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. <i>Thromb Haemost.</i> 1997; <b>77</b>(4): 660–7. <a target=xrefwindow id=d3141e2250 href="http://www.ncbi.nlm.nih.gov/pubmed/9134639">PubMed Abstract </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d3141e2259 class=n-a></a>Giles AR, Rivard GE, Teitel J, <i> et al.</i>: Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. <i>Transfus Sci.</i> 1998; <b>19</b>(2): 139–48. <a target=xrefwindow id=d3141e2270 href="http://www.ncbi.nlm.nih.gov/pubmed/10187039">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2273 href="http://dx.doi.org/10.1016/S0955-3886(98)00024-1">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d3141e2283 class=n-a></a>Hay CR, Palmer BP, Chalmers EA, <i> et al.</i>: The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison. <i>Haemophilia.</i> 2015; <b>21</b>(2): 219–26. <a target=xrefwindow id=d3141e2294 href="http://www.ncbi.nlm.nih.gov/pubmed/25382829">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2297 href="http://dx.doi.org/10.1111/hae.12563">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d3141e2306 class=n-a></a>Lee CA: The natural history of HIV disease in haemophilia. <i>Blood Rev.</i> 1998; <b>12</b>(3): 135–44. <a target=xrefwindow id=d3141e2314 href="http://www.ncbi.nlm.nih.gov/pubmed/9745883">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2317 href="http://dx.doi.org/10.1016/S0268-960X(98)90011-X%0A">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d3141e2326 class=n-a></a>White GC: Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure. <i>Trans Am Clin Climatol Assoc.</i> 2010; <b>121</b>: 61–73; discussion 4–5. <a target=xrefwindow id=d3141e2334 href="http://www.ncbi.nlm.nih.gov/pubmed/20697550">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2337 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2917149">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717973234"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2346 class=n-a></a>Gouw SC, van der Bom JG, Ljung R, <i> et al.</i>: Factor VIII products and inhibitor development in severe hemophilia A. <i>N Engl J Med.</i> 2013; <b>368</b>(3): 231–9. <a target=xrefwindow id=d3141e2357 href="http://www.ncbi.nlm.nih.gov/pubmed/23323899">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2360 href="http://dx.doi.org/10.1056/NEJMoa1208024">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717973234">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d3141e2373 class=n-a></a>Iorio A, Halimeh S, Holzhauer S, <i> et al.</i>: Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. <i>J Thromb Haemost.</i> 2010; <b>8</b>(6): 1256–65. <a target=xrefwindow id=d3141e2384 href="http://www.ncbi.nlm.nih.gov/pubmed/20345722">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2387 href="http://dx.doi.org/10.1111/j.1538-7836.2010.03823.x">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d3141e2396 class=n-a></a>Franchini M, Tagliaferri A, Mengoli C, <i> et al.</i>: Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. <i>Crit Rev Oncol Hematol.</i> 2012; <b>81</b>(1): 82–93. <a target=xrefwindow id=d3141e2407 href="http://www.ncbi.nlm.nih.gov/pubmed/21277222">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2410 href="http://dx.doi.org/10.1016/j.critrevonc.2011.01.002">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727542810"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2420 class=n-a></a>Lai J, Hough C, Tarrant J, <i> et al.</i>: Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. <i>Blood.</i> 2017; <b>129</b>(24): 3147–54. <a target=xrefwindow id=d3141e2431 href="http://www.ncbi.nlm.nih.gov/pubmed/28432221">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2434 href="http://dx.doi.org/10.1182/blood-2016-11-750885">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727542810">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726378843"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2447 class=n-a></a>Peyvandi F, Mannucci PM, Garagiola I, <i> et al.</i>: A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. <i>N Engl J Med.</i> 2016; <b>374</b>(21): 2054–64. <a target=xrefwindow id=d3141e2458 href="http://www.ncbi.nlm.nih.gov/pubmed/27223147">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2461 href="http://dx.doi.org/10.1056/NEJMoa1516437">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726378843">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d3141e2474 class=n-a></a>DiMichele DM: Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication. <i>Pediatr Blood Cancer.</i> 2013; <b>60 Suppl 1</b>: S30–3. <a target=xrefwindow id=d3141e2482 href="http://www.ncbi.nlm.nih.gov/pubmed/23109404">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2485 href="http://dx.doi.org/10.1002/pbc.24338">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727874752"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2494 class=n-a></a>Rosendaal FR, Palla R, Garagiola I, <i> et al.</i>: Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. <i>Blood.</i> 2017; <b>130</b>(15): 1757–9. <a target=xrefwindow id=d3141e2505 href="http://www.ncbi.nlm.nih.gov/pubmed/28768627">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2508 href="http://dx.doi.org/10.1182/blood-2017-06-791756">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727874752">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d3141e2521 class=n-a></a>Remington KM, Trejo SR, Buczynski G, <i> et al.</i>: Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. <i>Vox Sang.</i> 2004; <b>87</b>(1): 10–8. <a target=xrefwindow id=d3141e2532 href="http://www.ncbi.nlm.nih.gov/pubmed/15260817">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2535 href="http://dx.doi.org/10.1111/j.1423-0410.2004.00530.x">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727146737"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2544 class=n-a></a>Kühnel D, Müller S, Pichotta A, <i> et al.</i>: Inactivation of Zika virus by solvent/detergent treatment of human plasma and other plasma-derived products and pasteurization of human serum albumin. <i>Transfusion.</i> 2017; <b>57</b>(3pt2): 802–10. <a target=xrefwindow id=d3141e2555 href="http://www.ncbi.nlm.nih.gov/pubmed/28019034">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2558 href="http://dx.doi.org/10.1111/trf.13964">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727146737">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d3141e2572 class=n-a></a>Millar CM: vCJD and hemophilia. <i>Textbook of Hemophilia</i>, 3. 2014; 277–82. <a target=xrefwindow id=d3141e2577 href="http://dx.doi.org/10.1002/9781118398258.ch39">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727795752"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2586 class=n-a></a>Oldenburg J, Mahlangu JN, Kim B, <i> et al.</i>: Emicizumab Prophylaxis in Hemophilia A with Inhibitors. <i>N Engl J Med.</i> 2017; <b>377</b>(9): 809–818. <a target=xrefwindow id=d3141e2597 href="http://www.ncbi.nlm.nih.gov/pubmed/28691557">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2600 href="http://dx.doi.org/10.1056/NEJMoa1703068">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727795752">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725980063"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2613 class=n-a></a>Uchida N, Sambe T, Yoneyama K, <i> et al.</i>: A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. <i>Blood.</i> 2016; <b>127</b>(13): 1633–41. <a target=xrefwindow id=d3141e2624 href="http://www.ncbi.nlm.nih.gov/pubmed/26626991">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2627 href="http://dx.doi.org/10.1182/blood-2015-06-650226">Publisher Full Text </a> | <a target=xrefwindow id=d3141e2631 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4817308">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725980063">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726378844"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2644 class=n-a></a>Shima M, Hanabusa H, Taki M, <i> et al.</i>: Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. <i>N Engl J Med.</i> 2016; <b>374</b>(21): 2044–53. <a target=xrefwindow id=d3141e2655 href="http://www.ncbi.nlm.nih.gov/pubmed/27223146">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2658 href="http://dx.doi.org/10.1056/NEJMoa1511769">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726378844">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717960353"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2671 class=n-a></a>Kitazawa T, Igawa T, Sampei Z, <i> et al.</i>: A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. <i>Nat Med.</i> 2012; <b>18</b>(10): 1570–4. <a target=xrefwindow id=d3141e2682 href="http://www.ncbi.nlm.nih.gov/pubmed/23023498">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2685 href="http://dx.doi.org/10.1038/nm.2942">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717960353">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d3141e2698 class=n-a></a>Sehgal A, Barros S, Ivanciu L, <i> et al.</i>: An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. <i>Nat Med.</i> 2015; <b>21</b>(5): 492–7. <a target=xrefwindow id=d3141e2709 href="http://www.ncbi.nlm.nih.gov/pubmed/25849132">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2712 href="http://dx.doi.org/10.1038/nm.3847">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727795736"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2722 class=n-a></a>Pasi KJ, Rangarajan S, Georgiev P, <i> et al.</i>: Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. <i>N Engl J Med.</i> 2017; <b>377</b>(9): 819–828. <a target=xrefwindow id=d3141e2733 href="http://www.ncbi.nlm.nih.gov/pubmed/28691885">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2736 href="http://dx.doi.org/10.1056/NEJMoa1616569">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727795736">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d3141e2749 class=n-a></a>Chowdary P, Lethagen S, Friedrich U, <i> et al.</i>: Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. <i>J Thromb Haemost.</i> 2015; <b>13</b>(5): 743–54. <a target=xrefwindow id=d3141e2760 href="http://www.ncbi.nlm.nih.gov/pubmed/25641556">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2763 href="http://dx.doi.org/10.1111/jth.12864">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d3141e2772 class=n-a></a>Hilden I, Lauritzen B, Sørensen BB, <i> et al.</i>: Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. <i>Blood.</i> 2012; <b>119</b>(24): 5871–8. <a target=xrefwindow id=d3141e2783 href="http://www.ncbi.nlm.nih.gov/pubmed/22563084">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2786 href="http://dx.doi.org/10.1182/blood-2012-01-401620">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d3141e2795 class=n-a></a>Jasuja R, Barakat A, Murphy JE, <i> et al.</i>: An Antibody to Tissue Factor Pathway Inhibitor (TFPI) Restores Hemostasis after the Onset of Bleeding in Hemophilic a Mouse Injury Models. Paper presented at: Annual Meeting of the American Society of Hematology; San Diego, USA. <i>Blood.</i> 2016; <b>128</b>(22): 3761. <a target=xrefwindow id=d3141e2806 href="http://www.bloodjournal.org/content/128/22/3761?sso-checked=true">Reference Source</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728642785"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2815 class=n-a></a>Waters EK, Sigh J, Friedrich U, <i> et al.</i>: Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. <i>Haemophilia.</i> 2017; <b>23</b>(5): 769–76. <a target=xrefwindow id=d3141e2826 href="http://www.ncbi.nlm.nih.gov/pubmed/28594458">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2829 href="http://dx.doi.org/10.1111/hae.13260">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728642785">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727623696"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2842 class=n-a></a>Gu JM, Zhao XY, Schwarz T, <i> et al.</i>: Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys. <i>AAPS J.</i> 2017; <b>19</b>(4): 1186–95. <a target=xrefwindow id=d3141e2853 href="http://www.ncbi.nlm.nih.gov/pubmed/28516358">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2856 href="http://dx.doi.org/10.1208/s12248-017-0086-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727623696">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727580165"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e2870 class=n-a></a>Hamedani NS, Ruhl H, Zimmermann JJ, <i> et al.</i>: <i>In Vitro</i> Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach. <i>Nucleic Acid Ther.</i> 2016; <b>26</b>(6): 355–62. <a target=xrefwindow id=d3141e2884 href="http://www.ncbi.nlm.nih.gov/pubmed/27736370">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2888 href="http://dx.doi.org/10.1089/nat.2016.0645">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727580165">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d3141e2901 class=n-a></a>Polderdijk SGI, Baglin TP, Huntington JA: Targeting activated protein C to treat hemophilia. <i>Curr Opin Hematol.</i> 2017; <b>24</b>(5): 446–52. <a target=xrefwindow id=d3141e2909 href="http://www.ncbi.nlm.nih.gov/pubmed/28632502">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2912 href="http://dx.doi.org/10.1097/MOH.0000000000000364">Publisher Full Text </a> | <a target=xrefwindow id=d3141e2915 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5548501">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d3141e2924 class=n-a></a>Antunes SV, Tangada S, Stasyshyn O, <i> et al.</i>: Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. <i>Haemophilia.</i> 2014; <b>20</b>(1): 65–72. <a target=xrefwindow id=d3141e2935 href="http://www.ncbi.nlm.nih.gov/pubmed/23910578">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2938 href="http://dx.doi.org/10.1111/hae.12246">Publisher Full Text </a> | <a target=xrefwindow id=d3141e2942 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4216433">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d3141e2951 class=n-a></a>Konkle BA, Ebbesen LS, Erhardtsen E, <i> et al.</i>: Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. <i>J Thromb Haemost.</i> 2007; <b>5</b>(9): 1904–13. <a target=xrefwindow id=d3141e2962 href="http://www.ncbi.nlm.nih.gov/pubmed/17723130">PubMed Abstract </a> | <a target=xrefwindow id=d3141e2965 href="http://dx.doi.org/10.1111/j.1538-7836.2007.02663.x">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d3141e2974 class=n-a></a>Negrier C, Berruyer M, Durin A, <i> et al.</i>: Increased thrombin generation in a child with a combined factor IX and protein C deficiency. <i>Blood.</i> 1993; <b>81</b>(3): 690–5. <a target=xrefwindow id=d3141e2985 href="http://www.ncbi.nlm.nih.gov/pubmed/8427961">PubMed Abstract </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d3141e2994 class=n-a></a>Kurnik K, Kreuz W, Horneff S, <i> et al.</i>: Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys. <i>Haematologica.</i> 2007; <b>92</b>(7): 982–5. <a target=xrefwindow id=d3141e3005 href="http://www.ncbi.nlm.nih.gov/pubmed/17606451">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3008 href="http://dx.doi.org/10.3324/haematol.11161">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d3141e3018 class=n-a></a>Escuriola Ettingshausen C, Halimeh S, Kurnik K, <i> et al.</i>: Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. <i>Thromb Haemost.</i> 2001; <b>85</b>(2): 218–20. <a target=xrefwindow id=d3141e3029 href="http://www.ncbi.nlm.nih.gov/pubmed/11246535">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3032 href="http://dx.doi.org/10.1007/978-3-642-59383-3_9">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d3141e3041 class=n-a></a>Shetty S, Vora S, Kulkarni B, <i> et al.</i>: Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. <i>Br J Haematol.</i> 2007; <b>138</b>(4): 541–4. <a target=xrefwindow id=d3141e3052 href="http://www.ncbi.nlm.nih.gov/pubmed/17659055">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3055 href="http://dx.doi.org/10.1111/j.1365-2141.2007.06693.x">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d3141e3064 class=n-a></a>Schlachterman A, Schuettrumpf J, Liu JH, <i> et al.</i>: Factor V Leiden improves <i>in vivo</i> hemostasis in murine hemophilia models. <i>J Thromb Haemost.</i> 2005; <b>3</b>(12): 2730–7. <a target=xrefwindow id=d3141e3078 href="http://www.ncbi.nlm.nih.gov/pubmed/16359510">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3082 href="http://dx.doi.org/10.1111/j.1538-7836.2005.01639.x">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d3141e3091 class=n-a></a>Willyard C: Thrombosis: Balancing act. <i>Nature.</i> 2014; <b>515</b>(7528): S168–S9. <a target=xrefwindow id=d3141e3099 href="http://www.ncbi.nlm.nih.gov/pubmed/25427209">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3102 href="http://dx.doi.org/10.1038/515S168a">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d3141e3111 class=n-a></a>Luu H, Ewenstein B: FEIBA safety profile in multiple modes of clinical and home-therapy application. <i>Haemophilia.</i> 2004; <b>10 Suppl 2</b>: 10–6. <a target=xrefwindow id=d3141e3119 href="http://www.ncbi.nlm.nih.gov/pubmed/15385041">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3122 href="http://dx.doi.org/10.1111/j.1365-2516.2004.00935.x">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d3141e3131 class=n-a></a>Turecek PL, Váradi K, Gritsch H, <i> et al.</i>: FEIBA: mode of action. <i>Haemophilia.</i> 2004; <b>10 Suppl 2</b>: 3–9. <a target=xrefwindow id=d3141e3142 href="http://www.ncbi.nlm.nih.gov/pubmed/15385040">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3145 href="http://dx.doi.org/10.1111/j.1365-2516.2004.00934.x">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d3141e3155 class=n-a></a>Hartmann R, Feenstra T, Knappe S, <i> et al.</i>: Synergistic Interplay of A Sequence Analog of ACE910, a Bispecific Antibody, and a Bypassing Reasgent and its Components. Paper presented at: Congress of the International Society of Thrombosis and Haemostasis; Berlin, Germany. 2017. </span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d3141e3167 class=n-a></a>Yada K, Nogami K, Kitazawa T, <i> et al.</i>: Mode of Enhancement in the Global Hemostatic Potential with Concomitant Use of Bypassing Agents and Emicizumab in Hemophilia A Patients with Inhibitor Evaluated by Rotem. Paper presented at: Congress of the International Society of Thrombosis and Haemostasis; Berlin, Germany. 2017. </span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d3141e3179 class=n-a></a>Lenting PJ, Denis CV, Christophe OD: Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? <i>Blood.</i> 2017; <b>130</b>(23): 2463–2468. <a target=xrefwindow id=d3141e3187 href="http://www.ncbi.nlm.nih.gov/pubmed/29042366">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3190 href="http://dx.doi.org/10.1182/blood-2017-08-801662">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d3141e3199 class=n-a></a>Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs [press release]. Cambridge, MA: Business Wire, September 7, 2017. <a target=xrefwindow id=d3141e3201 href="https://www.bioportfolio.com/news/pdf/3306510/Alnylam-Provides-Pipeline-Update-on-Fitusiran-and-Givosiran-Investigational-RNAi-Therapeutic-Programs.pdf">Reference Source</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d3141e3210 class=n-a></a>Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. <i>Lancet.</i> 1995; <b>346</b>(8983): 1133–4. <a target=xrefwindow id=d3141e3218 href="http://www.ncbi.nlm.nih.gov/pubmed/7475606">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3221 href="http://dx.doi.org/10.1016/S0140-6736(95)91803-5">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14242957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e3230 class=n-a></a>Hay CR, DiMichele DM, International Immune Tolerance Study: The principal results of the International Immune Tolerance Study: a randomized dose comparison. <i>Blood.</i> 2012; <b>119</b>(6): 1335–44. <a target=xrefwindow id=d3141e3238 href="http://www.ncbi.nlm.nih.gov/pubmed/22101900">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3241 href="http://dx.doi.org/10.1182/blood-2011-08-369132">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14242957">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d3141e3255 class=n-a></a>Van Dijk K, Van Der Bom JG, Bax KN, <i> et al.</i>: Use of implantable venous access devices in children with severe hemophilia: benefits and burden. <i>Haematologica.</i> 2004; <b>89</b>(2): 189–94. <a target=xrefwindow id=d3141e3266 href="http://www.ncbi.nlm.nih.gov/pubmed/15003894">PubMed Abstract </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d3141e3275 class=n-a></a>Batsuli G, Meeks SL, Herzog RW, <i> et al.</i>: Innovating immune tolerance induction for haemophilia. <i>Haemophilia.</i> 2016; <b>22 Suppl 5</b>: 31–5. <a target=xrefwindow id=d3141e3286 href="http://www.ncbi.nlm.nih.gov/pubmed/27405673">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3289 href="http://dx.doi.org/10.1111/hae.12989">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d3141e3298 class=n-a></a>Arruda VR, Samelson-Jones BJ: Gene therapy for immune tolerance induction in hemophilia with inhibitors. <i>J Thromb Haemost.</i> 2016; <b>14</b>(6): 1121–34. <a target=xrefwindow id=d3141e3306 href="http://www.ncbi.nlm.nih.gov/pubmed/27061380">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3309 href="http://dx.doi.org/10.1111/jth.13331">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3312 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4907803">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726223554"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e3321 class=n-a></a>Mazepa MA, Monahan PE, Baker JR, <i> et al.</i>: Men with severe hemophilia in the United States: birth cohort analysis of a large national database. <i>Blood.</i> 2016; <b>127</b>(24): 3073–81. <a target=xrefwindow id=d3141e3332 href="http://www.ncbi.nlm.nih.gov/pubmed/26983851">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3335 href="http://dx.doi.org/10.1182/blood-2015-10-675140">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3339 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4911863">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726223554">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d3141e3352 class=n-a></a>Franchini M, Mannucci PM: Direct oral anticoagulants and venous thromboembolism. <i>Eur Respir Rev.</i> 2016; <b>25</b>(141): 295–302. <a target=xrefwindow id=d3141e3360 href="http://www.ncbi.nlm.nih.gov/pubmed/27581829">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3363 href="http://dx.doi.org/10.1183/16000617.0025-2016">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d3141e3372 class=n-a></a>Rivard GE, Lillicrap D, Poon MC, <i> et al.</i>: Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age? <i>Haemophilia.</i> 2005; <b>11</b>(4): 335–9. <a target=xrefwindow id=d3141e3383 href="http://www.ncbi.nlm.nih.gov/pubmed/16011584">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3386 href="http://dx.doi.org/10.1111/j.1365-2516.2005.01088.x">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d3141e3396 class=n-a></a>Eckhardt CL, van Velzen AS, Peters M, <i> et al.</i>: Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. <i>Blood.</i> 2013; <b>122</b>(11): 1954–62. <a target=xrefwindow id=d3141e3407 href="http://www.ncbi.nlm.nih.gov/pubmed/23926300">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3410 href="http://dx.doi.org/10.1182/blood-2013-02-483263">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725364109"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e3419 class=n-a></a>Du Toit G, Roberts G, Sayre PH, <i> et al.</i>: Randomized trial of peanut consumption in infants at risk for peanut allergy. <i>N Engl J Med.</i> 2015; <b>372</b>(9): 803–13. <a target=xrefwindow id=d3141e3430 href="http://www.ncbi.nlm.nih.gov/pubmed/25705822">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3433 href="http://dx.doi.org/10.1056/NEJMoa1414850">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3437 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4416404">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725364109">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d3141e3450 class=n-a></a>Lövgren KM, Sondergaard H, Skov S, <i> et al.</i>: Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models. <i>Haemophilia.</i> 2016; <b>22</b>(5): 657–66. <a target=xrefwindow id=d3141e3461 href="http://www.ncbi.nlm.nih.gov/pubmed/27562315">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3464 href="http://dx.doi.org/10.1111/hae.13075">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d3141e3473 class=n-a></a>High KA: The gene therapy journey for hemophilia: are we there yet? <i>Hematology Am Soc Hematol Educ Program.</i> 2012; <b>2012</b>: 375–81. <a target=xrefwindow id=d3141e3481 href="http://www.ncbi.nlm.nih.gov/pubmed/23233607">PubMed Abstract </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d3141e3490 class=n-a></a>Lheriteau E, Davidoff AM, Nathwani AC: Haemophilia gene therapy: Progress and challenges. <i>Blood Rev.</i> 2015; <b>29</b>(5): 321–8. <a target=xrefwindow id=d3141e3498 href="http://www.ncbi.nlm.nih.gov/pubmed/26049173">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3501 href="http://dx.doi.org/10.1016/j.blre.2015.03.002">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d3141e3510 class=n-a></a>Rogers GL, Herzog RW: Gene therapy for hemophilia. <i>Front Biosci (Landmark Ed).</i> 2015; <b>20</b>: 556–603. <a target=xrefwindow id=d3141e3518 href="http://www.ncbi.nlm.nih.gov/pubmed/25553466">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3521 href="http://dx.doi.org/10.2741/4324">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3524 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4476626">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1031147"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e3534 class=n-a></a>Manno CS, Pierce GF, Arruda VR, <i> et al.</i>: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. <i>Nat Med.</i> 2006; <b>12</b>(3): 342–7. <a target=xrefwindow id=d3141e3545 href="http://www.ncbi.nlm.nih.gov/pubmed/16474400">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3548 href="http://dx.doi.org/10.1038/nm1358">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1031147">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d3141e3561 class=n-a></a>Calcedo R, Morizono H, Wang L, <i> et al.</i>: Adeno-associated virus antibody profiles in newborns, children, and adolescents. <i>Clin Vaccine Immunol.</i> 2011; <b>18</b>(9): 1586–8. <a target=xrefwindow id=d3141e3572 href="http://www.ncbi.nlm.nih.gov/pubmed/21775517">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3575 href="http://dx.doi.org/10.1128/CVI.05107-11">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3579 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3165215">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d3141e3588 class=n-a></a>Arruda VR, Samelson-Jones BJ: Obstacles and future of gene therapy for hemophilia. <i>Expert Opin Orphan Drugs.</i> 2015; <b>3</b>(9): 997–1010. <a target=xrefwindow id=d3141e3596 href="http://www.ncbi.nlm.nih.gov/pubmed/26900534">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3599 href="http://dx.doi.org/10.1517/21678707.2015.1069179">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3602 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4756761">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d3141e3611 class=n-a></a>Mingozzi F, High KA: Immune responses to AAV in clinical trials. <i>Curr Gene Ther.</i> 2011; <b>11</b>(4): 321–30. <a target=xrefwindow id=d3141e3619 href="http://www.ncbi.nlm.nih.gov/pubmed/21557723">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3622 href="http://dx.doi.org/10.2174/156652311796150354">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d3141e3631 class=n-a></a>Ertl HCJ, High KA: Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy. <i>Hum Gene Ther.</i> 2017; <b>28</b>(4): 328–37. <a target=xrefwindow id=d3141e3639 href="http://www.ncbi.nlm.nih.gov/pubmed/28042943">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3642 href="http://dx.doi.org/10.1089/hum.2016.172">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d3141e3651 class=n-a></a>Srivastava A: <i>In vivo</i> tissue-tropism of adeno-associated viral vectors. <i>Curr Opin Virol.</i> 2016; <b>21</b>: 75–80. <a target=xrefwindow id=d3141e3662 href="http://www.ncbi.nlm.nih.gov/pubmed/27596608">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3665 href="http://dx.doi.org/10.1016/j.coviro.2016.08.003">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3669 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5138125">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d3141e3679 class=n-a></a>Choo KH, Gould KG, Rees DJ, <i> et al.</i>: Molecular cloning of the gene for human anti-haemophilic factor IX. <i>Nature.</i> 1982; <b>299</b>(5879): 178–80. <a target=xrefwindow id=d3141e3690 href="http://www.ncbi.nlm.nih.gov/pubmed/6287289">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3693 href="http://dx.doi.org/10.1038/299178a0">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d3141e3702 class=n-a></a>Lind P, Larsson K, Spira J, <i> et al.</i>: Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. <i>Eur J Biochem.</i> 1995; <b>232</b>(1): 19–27. <a target=xrefwindow id=d3141e3713 href="http://www.ncbi.nlm.nih.gov/pubmed/7556150">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3716 href="http://dx.doi.org/10.1111/j.1432-1033.1995.tb20776.x">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d3141e3725 class=n-a></a>Nathwani AC, Reiss UM, Tuddenham EG, <i> et al.</i>: Long-term safety and efficacy of factor IX gene therapy in hemophilia B. <i>N Engl J Med.</i> 2014; <b>371</b>(21): 1994–2004. <a target=xrefwindow id=d3141e3736 href="http://www.ncbi.nlm.nih.gov/pubmed/25409372">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3739 href="http://dx.doi.org/10.1056/NEJMoa1407309">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3743 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4278802">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13409045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e3752 class=n-a></a>Nathwani AC, Tuddenham EG, Rangarajan S, <i> et al.</i>: Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. <i>N Engl J Med.</i> 2011; <b>365</b>(25): 2357–65. <a target=xrefwindow id=d3141e3763 href="http://www.ncbi.nlm.nih.gov/pubmed/22149959">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3766 href="http://dx.doi.org/10.1056/NEJMoa1108046">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3770 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3265081">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13409045">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732234317"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e3783 class=n-a></a>George LA, Sullivan SK, Giermasz A, <i> et al.</i>: Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. <i>N Engl J Med.</i> 2017; <b>377</b>(23): 2215–27. <a target=xrefwindow id=d3141e3794 href="http://www.ncbi.nlm.nih.gov/pubmed/29211678">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3797 href="http://dx.doi.org/10.1056/NEJMoa1708538">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732234317">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d3141e3810 class=n-a></a>Simioni P, Tormene D, Tognin G, <i> et al.</i>: X-linked thrombophilia with a mutant factor IX (factor IX Padua). <i>N Engl J Med.</i> 2009; <b>361</b>(17): 1671–5. <a target=xrefwindow id=d3141e3821 href="http://www.ncbi.nlm.nih.gov/pubmed/19846852">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3824 href="http://dx.doi.org/10.1056/NEJMoa0904377">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d3141e3834 class=n-a></a>Miesbach W, Meijer K, Coppens M, <i> et al.</i>: Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. <i>Blood.</i> 2018; <b>131</b>(9): 1022–1031. <a target=xrefwindow id=d3141e3845 href="http://www.ncbi.nlm.nih.gov/pubmed/29246900">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3848 href="http://dx.doi.org/10.1182/blood-2017-09-804419">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3852 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5833265">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d3141e3861 class=n-a></a>Chapin J, Rottensteiner H, Scheiflinger F, <i> et al.</i>: An Analysis of Bleeding Rates and Factor IX Consumption in the Phase I/II BAX 335 Gene Therapy Trial in Subjects with Hemophilia B. Paper presented at: Congress of the International Society of Thrombosis and Haemostasis; Berlin, Germany. 2017. </span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d3141e3873 class=n-a></a>Monahan PE, Sun J, Gui T, <i> et al.</i>: Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. <i>Hum Gene Ther.</i> 2015; <b>26</b>(2): 69–81. <a target=xrefwindow id=d3141e3884 href="http://www.ncbi.nlm.nih.gov/pubmed/25419787">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3887 href="http://dx.doi.org/10.1089/hum.2014.106">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3891 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4326268">Free Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d3141e3900 class=n-a></a>Crudele JM, Finn JD, Siner JI, <i> et al.</i>: AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. <i>Blood.</i> 2015; <b>125</b>(10): 1553–61. <a target=xrefwindow id=d3141e3911 href="http://www.ncbi.nlm.nih.gov/pubmed/25568350">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3914 href="http://dx.doi.org/10.1182/blood-2014-07-588194">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3918 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4351503">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d3141e3927 class=n-a></a>Finn JD, Nichols TC, Svoronos N, <i> et al.</i>: The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. <i>Blood.</i> 2012; <b>120</b>(23): 4521–3. <a target=xrefwindow id=d3141e3938 href="http://www.ncbi.nlm.nih.gov/pubmed/22919027">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3941 href="http://dx.doi.org/10.1182/blood-2012-06-440123">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3945 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3512231">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d3141e3954 class=n-a></a>Antun A, Monahan PE, Manco-Johnson MJ, <i> et al.</i>: Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study. <i>J Thromb Haemost.</i> 2015; <b>13</b>(11): 1980–8. <a target=xrefwindow id=d3141e3965 href="http://www.ncbi.nlm.nih.gov/pubmed/26382916">PubMed Abstract </a> | <a target=xrefwindow id=d3141e3968 href="http://dx.doi.org/10.1111/jth.13143">Publisher Full Text </a> | <a target=xrefwindow id=d3141e3972 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4639409">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d3141e3982 class=n-a></a>Monahan PE, Walsh CE, Powell JS, <i> et al.</i>: Update on phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy for program for phemophilia B. <i>Journal of Thrombosis and Haemostasis.</i> 2015; <b>13</b>: 87. </span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d3141e4000 class=n-a></a>Rangarajan S, Walsh L, Lester W, <i> et al.</i>: AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. <i>N Engl J Med.</i> 2017; <b>377</b>(26): 2519–30. <a target=xrefwindow id=d3141e4011 href="http://www.ncbi.nlm.nih.gov/pubmed/29224506">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4014 href="http://dx.doi.org/10.1056/NEJMoa1708483">Publisher Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d3141e4023 class=n-a></a>Schuettrumpf J, Liu JH, Couto LB, <i> et al.</i>: Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial. <i>Mol Ther.</i> 2006; <b>13</b>(6): 1064–73. <a target=xrefwindow id=d3141e4034 href="http://www.ncbi.nlm.nih.gov/pubmed/16631412">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4037 href="http://dx.doi.org/10.1016/j.ymthe.2006.03.002">Publisher Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d3141e4046 class=n-a></a>Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, <i> et al.</i>: Clinical severity of haemophilia A: does the classification of the 1950s still stand? <i>Haemophilia.</i> 2011; <b>17</b>(6): 849–53. <a target=xrefwindow id=d3141e4057 href="http://www.ncbi.nlm.nih.gov/pubmed/21545376">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4060 href="http://dx.doi.org/10.1111/j.1365-2516.2011.02539.x">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d3141e4069 class=n-a></a>van Hylckama Vlieg A, van der Linden IK, Bertina RM, <i> et al.</i>: High levels of factor IX increase the risk of venous thrombosis. <i>Blood.</i> 2000; <b>95</b>(12): 3678–82. <a target=xrefwindow id=d3141e4080 href="http://www.ncbi.nlm.nih.gov/pubmed/10845896">PubMed Abstract </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d3141e4089 class=n-a></a>Kyrle PA, Minar E, Hirschl M, <i> et al.</i>: High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. <i>N Engl J Med.</i> 2000; <b>343</b>(7): 457–62. <a target=xrefwindow id=d3141e4100 href="http://www.ncbi.nlm.nih.gov/pubmed/10950667">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4103 href="http://dx.doi.org/10.1056/NEJM200008173430702">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d3141e4113 class=n-a></a>Koster T, Blann AD, Briët E, <i> et al.</i>: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. <i>Lancet.</i> 1995; <b>345</b>(8943): 152–5. <a target=xrefwindow id=d3141e4124 href="http://www.ncbi.nlm.nih.gov/pubmed/7823669">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4127 href="http://dx.doi.org/10.1016/S0140-6736(95)90166-3">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d3141e4136 class=n-a></a>Jenkins PV, Rawley O, Smith OP, <i> et al.</i>: Elevated factor VIII levels and risk of venous thrombosis. <i>Br J Haematol.</i> 2012; <b>157</b>(6): 653–63. <a target=xrefwindow id=d3141e4147 href="http://www.ncbi.nlm.nih.gov/pubmed/22530883">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4150 href="http://dx.doi.org/10.1111/j.1365-2141.2012.09134.x">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d3141e4159 class=n-a></a>Bertina RM: Elevated clotting factor levels and venous thrombosis. <i>Pathophysiol Haemost Thromb.</i> 2003; <b>33</b>(5–6): 395–400. <a target=xrefwindow id=d3141e4167 href="http://www.ncbi.nlm.nih.gov/pubmed/15692250">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4170 href="http://dx.doi.org/10.1159/000083835">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d3141e4179 class=n-a></a>Rosendaal FR: High levels of factor VIII and venous thrombosis. <i>Thromb Haemost.</i> 2000; <b>83</b>(1): 1–2. <a target=xrefwindow id=d3141e4187 href="http://www.ncbi.nlm.nih.gov/pubmed/10669143">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4190 href="http://dx.doi.org/10.1055/s-0037-1613745">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d3141e4199 class=n-a></a>Mannucci PM, Schutgens RE, Santagostino E, <i> et al.</i>: How I treat age-related morbidities in elderly persons with hemophilia. <i>Blood.</i> 2009; <b>114</b>(26): 5256–63. <a target=xrefwindow id=d3141e4210 href="http://www.ncbi.nlm.nih.gov/pubmed/19837978">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4213 href="http://dx.doi.org/10.1182/blood-2009-07-215665">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d3141e4222 class=n-a></a>Srámek A, Kriek M, Rosendaal FR: Decreased mortality of ischaemic heart disease among carriers of haemophilia. <i>Lancet.</i> 2003; <b>362</b>(9381): 351–4. <a target=xrefwindow id=d3141e4230 href="http://www.ncbi.nlm.nih.gov/pubmed/12907007">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4233 href="http://dx.doi.org/10.1016/S0140-6736(03)14021-4">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725087086"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e4243 class=n-a></a>Mauro VP, Chappell SA: A critical analysis of codon optimization in human therapeutics. <i>Trends Mol Med.</i> 2014; <b>20</b>(11): 604–13. <a target=xrefwindow id=d3141e4251 href="http://www.ncbi.nlm.nih.gov/pubmed/25263172">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4254 href="http://dx.doi.org/10.1016/j.molmed.2014.09.003">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4257 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4253638">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725087086">F1000 Recommendation</a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727227137"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e4270 class=n-a></a>Shestopal SA, Hao JJ, Karnaukhova E, <i> et al.</i>: Expression and characterization of a codon-optimized blood coagulation factor VIII. <i>J Thromb Haemost.</i> 2017; <b>15</b>(4): 709–20. <a target=xrefwindow id=d3141e4281 href="http://www.ncbi.nlm.nih.gov/pubmed/28109042">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4284 href="http://dx.doi.org/10.1111/jth.13632">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727227137">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d3141e4297 class=n-a></a>McIntosh J, Lenting PJ, Rosales C, <i> et al.</i>: Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. <i>Blood.</i> 2013; <b>121</b>(17): 3335–44. <a target=xrefwindow id=d3141e4308 href="http://www.ncbi.nlm.nih.gov/pubmed/23426947">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4311 href="http://dx.doi.org/10.1182/blood-2012-10-462200">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4315 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3637010">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d3141e4324 class=n-a></a>Niemeyer GP, Herzog RW, Mount J, <i> et al.</i>: Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. <i>Blood.</i> 2009; <b>113</b>(4): 797–806. <a target=xrefwindow id=d3141e4335 href="http://www.ncbi.nlm.nih.gov/pubmed/18957684">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4338 href="http://dx.doi.org/10.1182/blood-2008-10-181479">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4342 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2630266">Free Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d3141e4351 class=n-a></a>Callan MB, Haskins ME, Wang P, <i> et al.</i>: Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs. <i>PLoS One.</i> 2016; <b>11</b>(3): e0151800. <a target=xrefwindow id=d3141e4362 href="http://www.ncbi.nlm.nih.gov/pubmed/27011017">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4365 href="http://dx.doi.org/10.1371/journal.pone.0151800">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4369 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4807047">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d3141e4378 class=n-a></a>Smith RH, Levy JR, Kotin RM: A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. <i>Mol Ther.</i> 2009; <b>17</b>(11): 1888–96. <a target=xrefwindow id=d3141e4386 href="http://www.ncbi.nlm.nih.gov/pubmed/19532142">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4389 href="http://dx.doi.org/10.1038/mt.2009.128">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4392 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2835045">Free Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725719658"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e4402 class=n-a></a>Mietzsch M, Casteleyn V, Weger S, <i> et al.</i>: OneBac 2.0: <i>Sf</i>9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA. <i>Hum Gene Ther.</i> 2015; <b>26</b>(10): 688–97. <a target=xrefwindow id=d3141e4416 href="http://www.ncbi.nlm.nih.gov/pubmed/26134901">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4420 href="http://dx.doi.org/10.1089/hum.2015.050">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4423 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4842952">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725719658">F1000 Recommendation</a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d3141e4436 class=n-a></a>Urabe M, Nakakura T, Xin KQ, <i> et al.</i>: Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells. <i>J Virol.</i> 2006; <b>80</b>(4): 1874–85. <a target=xrefwindow id=d3141e4447 href="http://www.ncbi.nlm.nih.gov/pubmed/16439543">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4450 href="http://dx.doi.org/10.1128/JVI.80.4.1874-1885.2006">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4454 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1367135">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d3141e4463 class=n-a></a>George LA, Sullivan SK, Giermasz A, <i> et al.</i>: Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. <i>N Engl J Med.</i> 2017; <b>377</b>(23): 2215–27. <a target=xrefwindow id=d3141e4474 href="http://www.ncbi.nlm.nih.gov/pubmed/29211678">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4477 href="http://dx.doi.org/10.1056/NEJMoa1708538">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d3141e4486 class=n-a></a>Nathwani AC, Gray JT, McIntosh J, <i> et al.</i>: Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. <i>Blood.</i> 2007; <b>109</b>(4): 1414–21. <a target=xrefwindow id=d3141e4497 href="http://www.ncbi.nlm.nih.gov/pubmed/17090654">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4500 href="http://dx.doi.org/10.1182/blood-2006-03-010181">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4504 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1794053">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727580325"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3141e4513 class=n-a></a>Rogers GL, Shirley JL, Zolotukhin I, <i> et al.</i>: Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8<sup>+</sup> T cells. <i>Blood.</i> 2017; <b>129</b>(24): 3184–95. <a target=xrefwindow id=d3141e4527 href="http://www.ncbi.nlm.nih.gov/pubmed/28468798">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4531 href="http://dx.doi.org/10.1182/blood-2016-11-751040">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4534 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5472899">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727580325">F1000 Recommendation</a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d3141e4547 class=n-a></a>Sebode M, Hartl J, Vergani D, <i> et al.</i>: Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. <i>Liver Int.</i> 2018; <b>38</b>(1): 15–22. <a target=xrefwindow id=d3141e4558 href="http://www.ncbi.nlm.nih.gov/pubmed/28432836">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4561 href="http://dx.doi.org/10.1111/liv.13458">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d3141e4571 class=n-a></a>Arruda VR, Favaro P, Finn JD: Strategies to modulate immune responses: a new frontier for gene therapy. <i>Mol Ther.</i> 2009; <b>17</b>(9): 1492–503. <a target=xrefwindow id=d3141e4579 href="http://www.ncbi.nlm.nih.gov/pubmed/19584819">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4582 href="http://dx.doi.org/10.1038/mt.2009.150">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4585 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2835266">Free Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d3141e4594 class=n-a></a>Sack BK, Herzog RW, Terhorst C, <i> et al.</i>: Development of Gene Transfer for Induction of Antigen-specific Tolerance. <i>Mol Ther Methods Clin Dev.</i> 2014; <b>1</b>: 14013. <a target=xrefwindow id=d3141e4605 href="http://www.ncbi.nlm.nih.gov/pubmed/25558460">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4608 href="http://dx.doi.org/10.1038/mtm.2014.13">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4612 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4280786">Free Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d3141e4621 class=n-a></a>Finn JD, Ozelo MC, Sabatino DE, <i> et al.</i>: Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. <i>Blood.</i> 2010; <b>116</b>(26): 5842–8. <a target=xrefwindow id=d3141e4632 href="http://www.ncbi.nlm.nih.gov/pubmed/20876851">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4635 href="http://dx.doi.org/10.1182/blood-2010-06-288001">Publisher Full Text </a> | <a target=xrefwindow id=d3141e4639 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3031380">Free Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d3141e4648 class=n-a></a>Gavin DK: FDA statement regarding the use of adeno-associated virus reference standard materials. <i>Hum Gene Ther Methods.</i> 2015; <b>26</b>(1): 3. <a target=xrefwindow id=d3141e4656 href="http://www.ncbi.nlm.nih.gov/pubmed/25679057">PubMed Abstract </a> | <a target=xrefwindow id=d3141e4659 href="http://dx.doi.org/10.1089/hgtb.2015.1501">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 24 Apr 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-489.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-489.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> The Children's Hospital of Philadelphia, Philadelphia, PA, USA<br/> <sup>2</sup> Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA<br/> <sup>3</sup> Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, USA<br/> <p> <div class=margin-bottom> Valder R. Arruda <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Bhavya S. Doshi <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Benjamin J. Samelson-Jones <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-489/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 24 Apr 2018, 7:489 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.12491.1">https://doi.org/10.12688/f1000research.12491.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Arruda VR <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=13525 data-id=12491 data-downloads="" data-views="" data-scholar="10.12688/f1000research.12491.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-489/v1/pdf?article_uuid=c5614d1c-17a0-4441-94b1-f0ee8a75bae8" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.12491.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Arruda VR, Doshi BS and Samelson-Jones BJ. Emerging therapies for hemophilia: controversies and unanswered questions [version 1; peer review: 4 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):489 (<a href="https://doi.org/10.12688/f1000research.12491.1" target=_blank>https://doi.org/10.12688/f1000research.12491.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=12491 id=mobile-track-article-signin-12491 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/12491?target=/articles/7-489.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=13525 /> <input name=articleId type=hidden value=12491 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Qizhen Shi</strong>, Department of Pediatrics, Medical College of Wisconsin, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Pier Mannucci</strong>, Scientific Direction, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico and University of Milan, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Roland Herzog</strong>, Department of Pediatrics, University of Florida, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Steven Pipe</strong>, Pediatrics and Pathology, University of Michigan, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 24 Apr 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-489.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-489.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=33607-33166></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=33610-33167></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=33609-33168></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=33608-33169></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=4><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> <th class="c-report-timeline__headings-version p-article__color--dark">4</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-489/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>24 Apr 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Qizhen Shi</strong>, Department of Pediatrics, Medical College of Wisconsin, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Pier Mannucci</strong>, Scientific Direction, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico and University of Milan, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Roland Herzog</strong>, Department of Pediatrics, University of Florida, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Steven Pipe</strong>, Pediatrics and Pathology, University of Michigan, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-489.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-489/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Emerging therapies for hemophilia: controversies...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-489/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-489/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-489/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Arruda VR et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-489/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-489",
            templates : {
                twitter : "Emerging therapies for hemophilia: controversies and unanswered.... Arruda VR et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-489/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Emerging therapies for hemophilia: controversies and unanswered questions", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Emerging therapies for hemophilia: controversies and unanswered questions", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/12491/13525")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "13525");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "33168": 0,
                           "33169": 0,
                           "33166": 0,
                           "33167": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "61973a8f-d8bb-4c5b-93d5-b5bec5a1e8c5";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-489.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-489.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-489.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-489.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-489.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>